# EDGAR Filing Document

**Accession Number:** 0001949864
**File Stem:** 0001949864-23-000002
**Filing Date:** 2023-1
**Character Count:** 247093
**Document Hash:** e6879a177aa99ae170d4d18922c56929
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001949864-23-000002.hdr.sgml**: 20231121

**ACCESSION NUMBER**: 0001949864-23-000002

**CONFORMED SUBMISSION TYPE**: S-1/A

**PUBLIC DOCUMENT COUNT**: 9

**FILED AS OF DATE**: 20230130

**DATE AS OF CHANGE**: 20231023

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Mag Magna Corp.
- **CENTRAL INDEX KEY:** 0001949864
- **STANDARD INDUSTRIAL CLASSIFICATION:** MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833]
- **IRS NUMBER:** 981626237
- **STATE OF INCORPORATION:** WY
- **FISCAL YEAR END:** 0430

**FILING VALUES:**
- **FORM TYPE:** S-1/A
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-268561
- **FILM NUMBER:** 23566497

**BUSINESS ADDRESS:**
- **STREET 1:** 325 W WASHINGTON ST, STE 2877
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92103
- **BUSINESS PHONE:** 16204692043

**MAIL ADDRESS:**
- **STREET 1:** 325 W WASHINGTON ST, STE 2877
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92103

**UNITED STATES<br> SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**Amendment No. 1**

**FORM S-1**

**REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933**

**MAG MAGNA CORP**

(Exact name of registrant as specified in its charter)

**WYOMING**

(State or other jurisdiction of incorporation or organization)

**2810**

(Primary Standard Industrial Classification Code Number)

**98162-6237**

(I.R.S. Employer Identification Number)

**Oleg Bilinski**

**Chief Executive Officer**

**325 W Washington St**

**Ste 2877**

**San Diego, CA 92103**

**Phone number** +16204692043

**Email address** <u>office@magmagna.com</u>

(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)

**Registered Agents Inc.**

**30 N Gould St STE R**

**Sheridan, WY 82801**

(Name, address, including zip code, and telephone number, including area code, of agent for service)

**Approximate date of commencement of proposed sale to the public:** As soon as practicable after this Registration Statement is declared effective.

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box. ☐

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

Indicate by check mark whether the registrant is a large, accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company or an emerging growth company. See the definitions of "large, accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| Non-accelerated filer | ☐ | Smaller reporting company | ☒ |
| Emerging growth company | ☒ |  |  |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

**Calculation of Registration Fee** 

---

| | | | | |
|:---|:---|:---|:---|:---|
| &nbsp;&nbsp;Title of Each Class of Securities to<br> be Registered | &nbsp;&nbsp;Amount to be Registered <sup>(1)</sup> | &nbsp;&nbsp;Proposed Maximum Offering<br> Price Per Unit <sup>(2)</sup> | &nbsp;&nbsp;Proposed Maximum Aggregate Offering Price | &nbsp;&nbsp;Amount of Registration Fee |
| &nbsp;&nbsp;Common Stock, par value $0.001 per share | &nbsp;&nbsp;4000000 | &nbsp;&nbsp;$0.025 | &nbsp;&nbsp;$100000 | &nbsp;&nbsp;$15.00 |

---

<sup>(1)</sup> In the event of a stock split, stock dividend or similar transaction involving our common stock, the number of shares registered shall automatically be increased to cover the additional shares of common stock issuable pursuant to Rule 416 under the Securities Act of 1933, as amended.

<sup>(2)</sup> Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(a) of the Securities Act.

**The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until the Registration Statement shall become effective on such date as the Commission, acting pursuant to said Section 8(a), may determine.**

**PROSPECTUS** 

The information in this prospectus may be amended or completed. These securities may not be sold until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted. There is no minimum purchase requirement for the offering to proceed. We require minimum funding of approximately $25,000 to conduct our proposed operations for a period of one year.

**PRELIMINARY PROSPECTUS**

**MAG MAGNA CORP**

**4,000,000 SHARES OF COMMON STOCK**

**$0.025 PAR VALUE PER SHARE**

**Common Stock**

This is the initial offering of common stock of Mag Magna Corp and no public market currently exists for the securities being offered. We are registering for sale a total of 4,000,000 shares of common stock at a fixed price of $0.025 per share to the general public in best efforts offering. The shares will be offered at a fixed price of $0.025 per share for a period of three hundred and sixty-five (365) days from the Effective date of this prospectus. The offering shall terminate on the earlier of (i) when the offering period ends (365 days from the effective date of this prospectus), (ii) the date when the sale of all 4,000,000 shares is completed, (iii) when the Board of Director determines that it is in the best interest of the company to terminate the offering prior the completion of the sale of all 4,000,000 shares registered under the Registration Statement of which this prospectus is part.

The offering of the 4,000,000 shares is a "best effort" offering, which means that our sole officer and director, Oleg Bilinski, will use his best efforts to sell the common stock and there is no commitment by any person to purchase any shares. The shares will be offered at a fixed price of $0.025 per share for the duration of the offering. There is no minimum number of shares required to be sold to close the offering. Proceeds from the sale of the shares will be used to fund the initial stages of our business development. We have not made any arrangements to place funds received from share subscriptions in an escrow, trust or similar account. Any funds raised from the offering will be immediately available to us.

Following the completion of this offering, Mr. Bilinski will own 100% of our outstanding common stock if no shares are sold and 52.94% of our outstanding common stock if all 4,000,000 shares are sold. Due to this he can make and control corporate decisions that may be disadvantageous to minority shareholders.

Prior to this offering, there has been no public market for our shares. Upon completion of this Offering, we will attempt to have our shares quoted on the OTC Pink tier operated by the OTC Markets Group, Inc. There is no assurance that the Shares will ever be quoted on the OTC Pink. To be quoted on the OTC Pink, a market maker must apply to make a market in our common stock. As of the date of this Prospectus, we have not made any arrangement with any market makers to quote our shares.

We are an "emerging growth company" as defined in the Jumpstart Our Business Startups Act ("JOBS Act"). We are not a "shell company". We do not consider ourselves a "shell company" or a "blank check company". We are committed to implementing our business plan as described herewith in the Prospectus. The management of the Company does not have plans or intentions to acquire or to be merged with an operating company, nor does our management or any of our stakeholders, have plans to enter into a change of control transaction. As of the date of this Prospectus, there have been no written communications as defined under Rule 405 of the Securities Act to prospective investors or investors.

To date we have been involved primarily in organizational activities. We do not have sufficient capital to commence operations. Any investment in the shares offered herein involves a high degree of risk. You should only purchase shares if you can afford the loss of your investment. Our independent registered public accountant has issued an audit opinion which includes a statement expressing substantial doubt as to our ability to continue as a going concern.

**Investing in our common stock involves a high degree of risk. Before buying any shares, you should carefully read the discussion of the material risks of investing in our common stock under the heading "Risk Factors" starting on page 10 of this Prospectus.**

**Neither the Securities and Exchange Commission nor any state securities commission approved or disapproved of the securities that may be offered under this prospectus, nor have any of these organizations determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.**

The date of this prospectus is January 30, 2023.

**TABLE OF CONTENTS**

---

| | |
|:---|:---|
|  | &nbsp;&nbsp;Page |
| &nbsp;&nbsp;**PROSPECTUS SUMMARY** | 6 |
| &nbsp;&nbsp;**RISK FACTORS** | 10 |
| &nbsp;&nbsp;**SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS** | 25 |
| &nbsp;&nbsp;**USE OF PROCEEDS** | 26 |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp; DETERMINATION OF OFFERING PRICE<br> DIVIDEND POLICY | &nbsp;&nbsp; 27<br>27 |
| &nbsp;&nbsp;**CAPITALIZATION** | 27 |
| &nbsp;&nbsp;**DILUTION** | 27 |
| &nbsp;&nbsp;**MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS** | &nbsp;&nbsp; 28 |
| &nbsp;&nbsp;**BUSINESS** | 31 |
| &nbsp;&nbsp;**MANAGEMENT** | 34 |
| &nbsp;&nbsp;**EXECUTIVE COMPENSATION** | 36 |
| &nbsp;&nbsp;**CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS** | 36 |
| &nbsp;&nbsp; PRINCIPAL STOCKHOLDERS<br> PLAN OF DISTRIBUTION | &nbsp;&nbsp; 36<br>37 |
| &nbsp;&nbsp;**DESCRIPTION OF SECURITIES** | 39 |
| &nbsp;&nbsp;**LEGAL MATTERS** | 41 |
| &nbsp;&nbsp;**EXPERTS** | 41 |
| &nbsp;&nbsp;**WHERE YOU CAN FIND MORE INFORMATION** | 41 |
| &nbsp;&nbsp;**INDEX TO FINANCIAL STATEMENTS** | 43 |

---

**PROSPECTUS SUMMARY**

*This summary highlights information contained elsewhere in this prospectus. This summary does not contain all of the information you should consider before investing in our common stock. You should read this entire prospectus carefully, especially the sections titled "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations," and our financial statements and related notes included elsewhere in this prospectus, before making an investment decision. As used in this prospectus, unless the context otherwise requires, references to "we," "us," "our," "the Company", "Mag Magna Corp" refer to Mag Magna Corp.*

**Overview**

Mag Magna Corp is a Wyoming company incorporated on September 20, 2021. Mag Magna Corp is engaged in organizational activities and intends to expand the company's activities for distributing, marketing, and selling formula for feed additives, using new technologies in the near future.

Mag Magna Corp has a long-term partnership agreement with Ipax LLC ("Ipax"), a Wyoming company. Under the aforementioned Patent License and Assignment Agreement ("Agreement"), Mag Magna Corp has the exclusive right to distribute, market and sell a formula of feed additives that strengthens the immunity of poultry in the U.S. market.

According to the Agreement, Ipax provides a unique chemical composition of the formula and advisory services to Mag Magna Corp that is focused on improving, promoting, boosting, enhancing and distributing the formula for development of feed additives without antibiotics in the market. Together with Ipax, Mag Magna Corp distributes a methodology that allows raising poultry meat under industrial conditions, avoiding antibiotics at all stages of poultry breeding, both for therapeutic and prophylactic purposes. The two essential components are MAGA and CHASIS through which we can replace antibiotics with a more environmentally friendly formula. Mag Magna Corp is founded on an innovative approach, stability, confidentiality, and guarantee.

MAGA is a concentrated substance-immunostimulant for oral use. MAGA is an oily concentrate that dissolves well in water and has a characteristic smell of herbs and proves to be an essential component in poultry ration. Its properties include:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;● strengthening and stimulating the body's immune system;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;● ensuring energy exchange processes;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;● contributing to the restoration of optimal intestinal microflora;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;● eliminating inflammatory processes;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;● normalization of metabolism;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;● protecting from pathogenic microorganisms;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;● neutralizing the toxic manifestations;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;● activating enzyme reactions;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;● reducing the effect of stress factors;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;● bactericidal and hepatoprotective properties.

It is used to increase the assimilation of nutrients, eliminate intoxications, stimulate and normalize metabolism, increase the body`s general resistance, and normalize digestive processes.

The unique formula of "MAGA" has a bactericidal effect against gram-negative and gram-positive microorganisms, eliminates inflammatory processes in the gastrointestinal tract (including the oviduct in laying hens), inhibits toxic phenomena, preventing the accumulation of toxins from feed, has a general stimulating, tonic, adaptogen and anti-stress effect. The selected formulation, namely the composition of extracts: sprouts of wheat, wormwood, amaranth, nettle, magnesium chloride, etc., ensures normalization of metabolism in farm animals and poultry, improves the overall body resistance, regeneration of mucous membranes, increases the intensity and prolongation of egg production in laying hens, stimulates the digestive system, supplements the ovary of laying hens with macro- and microelements necessary for reproduction, increases the processes of poultry and animal weight information, has hepatoprotective properties.

CHASIS is a concentrate with a characteristic smell of wormwood. CHASIS is a feed additive that contains a stabilizer of intestinal microflora. This stabilizer is used to stimulate metabolic processes, prevent bacterial and viral diseases, and adapt to adverse environmental conditions. It helps to inhibit the growth of pathogenic enterobacteria and normalize intestinal microflora. Moreover, it stabilizes the digestive system, increases nonspecific resistance and metabolic processes, has a positive effect on productivity, reproduction, bird safety, normalizes intestinal passage, saves feed consumption, and improves feed digestibility.

The "CHASIS" feed additive is an active substance consisting of alkaloids obtained by the extraction of medicinal plants, which is a source of natural phyto components that are absorbed by 95-98%. Unique properties of the formulation improve performance in monogastric animals and poultry.

It normalizes the functioning of the gastrointestinal tract and microflora. It restores the optimal pH value in the gastrointestinal tract, increases body resistance to infections and toxin buildup, has anti-inflammatory antiseptic and hepatoprotective properties. It has an antimicrobial and virucidal effect, eliminates feed losses and improves its digestibility, and increases absorption of amino acids. It reduces oviduct inflammation (for laying hens), has an anthelmintic effect. It prevents oxidation of facts, fatty acids and sterols that may contribute to toxicosis. It improves general health of poultry, enhances feed conversion, egg production. The "CHASIS" feed additive contains no genetically modified substances.

The additive is used throughout the entire rearing period. It increases the efficiency of feeding and absorption of feed. It is used in the period of stress and prevention of infectious diseases, to optimize the absorption of nutrients, improves the adsorption of amino acids and reduces the number of mediators of inflammatory processes.

Product quality, safety, and the emergence and re-emergence of various diseases still present a challenge to the current market situation and future industry. Among the factors directly impacting the growth of the poultry industry are poultry immunity, health, and production. Foodborne and zoonotic diseases are strictly related to poultry. Spreading pathogens can represent a potential threat to human health. Apart from that, there are health hazards related to consuming foods with high antibiotic residues, and they remain a critical issue. However, it is necessary to point out that chickens are not susceptible to intranasal infection by the SARS-CoV-2 (COVID-19) virus.

Immunity is one of the key factors in protecting animals and controlling diseases. The health of animals is mediated by immunity and the risk of infection and invading pathogens. Chickens develop their immune system during various stages of life. They also depend on different types of immunity to protect themselves, such as natural or innate immunity from limiting pathogen growth.

Ipax registered both formulas 'CHASIS' and 'MAGA' in Eastern Europe. Please see Registration Certificates and Appendix to Registration certificates of MAGA and CHASIS filed as Exhibits 99.2-99.5.

**Our Industry**

<br> The United States has a robust poultry industry, which makes up a significant part of the country's agricultural economy. U.S. poultry farming is a large and growing sector, supported by competitive production structures, a variety of methods in poultry breeding, abundant domestic feed resources, and strong consumer appeal.

According to Poultry Global Market Report 2022, the global poultry market size is expected to grow to $493.21 billion in 2026 at a CAGR of 8.9%. Given the dynamics in the development of the poultry market, meat consumption in the U.S. is on the rise. The demand for chicken in the U.S. is linked to reduced consumption of beef and pork.

The U.S. Department of Agriculture ("USDA") claims U.S. poultry production has a competitive advantage in the world due to abundant domestic feed resources, mainly soybean meal and corn. Poultry feeding is the key to quality and healthy human food products such as meat and eggs. Modern poultry genetics drove a dramatic increase in poultry farming, requiring less feed and time to produce chickens ready for consumption and resulting in highly competitive product prices.

**Competition**

The poultry industry is highly competitive, and some of our competitors have greater financial and marketing resources than we do. In the United States, we compete with other vertically integrated poultry companies engaged in developing feed additives formulas.

In general, the competitive factors in the U.S. poultry industry include price, product quality, product development, brand identification, breadth of product line and customer service. Competitive factors vary by major market. In the feed additives market, we believe that competition is based on consistent quality, product development, service, and price. In the U.S. retail market, we believe that product quality, brand awareness and customer service are the primary bases of competition.

**Our Growth Strategy**

Our growth strategy is focused on these major areas:

Expansion And Optimization

Mag Magna Corp plans to establish and grow future partner relationships with companies, ready and willing to introduce alternatives to antibiotic feed additives. The initial focus is on optimizing existing properties of components and incrementally expanding the Company's capabilities. We have explored opportunities and increased demand for alternative feed additives that can be used to improve animal production, allowing us to take advantage of capacity expansion opportunities. Mr. Oleg Bilinski, our sole officer, and director, continually works to identify production bottlenecks and develop plans to eliminate them. Furthermore, the Company aims at capitalizing on prosperous export market trends for U.S. poultry feed.

Continued Product Innovation

The Company aims to coordinate with the partners to continually develop processes that meet their needs, including the opportunity to expand the depth and breadth of our further product offerings. The Agreement provides for the distribution, marketing, and sale of the feed additives formula. The Company is to operate in each of these directions, seeking strategic partners engaged in the development and manufacture of chemical compounds for feed additives becoming a prime focus. Providing a chemical formula, we foster further development and market entry of antibiotic-free products.

Mag Magna Corp was incorporated in Wyoming on September 20, 2021. Our principal executive office is located at 325 W Washington St Ste 2877 San Diego, CA 92103, and our telephone number is +16204692043. Our website address is <u>https://magmagna.com/</u>. The information contained in, or accessible through, our website does not constitute part of this prospectus.

**THE OFFERING**

---

| | |
|:---|:---|
| &nbsp;&nbsp;Common stock offered by us | &nbsp;&nbsp;4,000,000 shares |
| &nbsp;&nbsp;Common stock to be outstanding immediately after this offering | &nbsp;&nbsp;8,500,000 shares |
| &nbsp;&nbsp;Use of proceeds | &nbsp;&nbsp;We intend to use the net proceeds of this offering, together with our existing cash, to fund the continued development of the products and for working capital and general corporate purposes. See the section titled "Use of Proceeds." |
| &nbsp;&nbsp;Risk factors | &nbsp;&nbsp;See the section titled "Risk Factors" and other information included in this prospectus for a discussion of factors you should consider carefully before deciding to invest in our common stock. |

---

**Summary of Risks Related to Our Business**

Our ability to execute our business strategy is subject to numerous risks, as more fully described in "Risk Factors" immediately following this Prospectus Summary. These risks include, among others:

▪ Our operating results may fluctuate, and be difficult to predict, which may result in failing to meet expectations or any guidance we may provide.

▪ Our business is subject to risks arising from the COVID-19 pandemic and other epidemic diseases.

▪ Because we have a limited operating history, we may never generate any revenue or become profitable or, if we achieve profitability, we may not be able to sustain it.

▪ We cannot be certain that we will be able to obtain regulatory approval for, or successfully commercialize, any of our current or future product candidates.

▪ We currently have no marketing and sales organization and have no experience as a company in commercializing products, and we may need to invest significant resources to develop these capabilities. If we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell our products, we may not be able to generate product revenue.

▪ MAGA and CHASIS may prove to be difficult to effectively commercialize as planned.

**RISK FACTORS**

*Investing in our common stock involves a high degree of risk. You should consider carefully the risks and uncertainties described below, together with all of the other information in this prospectus, including our financial statements and related notes included elsewhere in this prospectus and the section titled "Management's Discussion and Analysis of Financial Condition and Results of Operations", before making an investment decision. If any of the following risks are realized, our business, financial condition, results of operations anв prospects could be materially and adversely affected. In that event, the trading price of our common stock could decline and you could lose part or all of your investment. Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations. This prospectus also contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in the forward-looking statements as a result of a number of factors, including the risks described below. See "Special Note Regarding Forward-Looking Statements."*

Risks Related to Our Business and Industry

 

*Our operating results may fluctuate, and be difficult to predict, which may result in failing to meet expectations or any guidance we may provide.*

Our future operating results may fluctuate significantly due to a number of factors, many of which are outside of our control, including, but not limited to:

&nbsp;&nbsp;&nbsp;&nbsp;▪ the level of demand for any approved products, which may vary significantly.

&nbsp;&nbsp;&nbsp;&nbsp;▪ expenditures that we may incur to develop or commercialize additional product
candidates and technologies.

&nbsp;&nbsp;&nbsp;&nbsp;▪ high product candidates' competition, or any change in the competitive
landscape of our industry, including consolidation among our competitors or partners; and

&nbsp;&nbsp;&nbsp;&nbsp;▪ future accounting pronouncements or changes in our accounting policies;
and

▪ changes in the demand for, and pricing of, products incorporating our product candidates.

The cumulative effects of these factors could result in large fluctuations and unpredictability in our quarterly and annual operating results.

This variability and unpredictability could also result in our failing to meet the expectations of industry or financial analysts or investors for any period. If our revenue or operating results fall below the expectations of analysts or investors or below any forecasts we may provide to the market, or if the forecasts we provide to the market are below the expectations of analysts or investors, the price of our common stock could decline substantially. Such a stock price decline could occur even when we have met any previously publicly stated revenue or earnings guidance we may provide.

*We may encounter difficulties in managing our growth and expanding our operations successfully.*

 

As our operations expand, we expect that we will need to manage additional relationships with various strategic partners, suppliers and other third parties. In addition, we may need to expand our facilities, including laboratory operations, and may be unable to do so on commercially reasonable terms, or at all. Our future financial performance and our ability to develop and commercialize our product candidates and to compete effectively will depend, in part, on our ability to manage any future growth effectively.

The expansion of our business and commercialization activities for our existing product candidates and further development of our product candidates are capital-intensive. We anticipate we may require additional financing to continue to fund our operations. Our future capital requirements will depend on, and could increase significantly as a result of, many factors including the costs, progress and timing of our efforts to approve and market out product candidates in the U.S. If funds are not available, we may be required to delay, reduce the scope of, or eliminate one or more of our commercialization efforts or our technologies, research, or development programs.

*Our business is subject to risks arising from the COVID-19 pandemic and other epidemic diseases.*

 

If a pandemic, epidemic or outbreak of an infectious disease occurs in the United States or elsewhere, our business may be adversely affected. COVID-19 has spread worldwide and has affected numerous economic sectors across

the world, including poultry production. The measures taken by authorities have impacted, and may further impact, poultry production systems, work operations, the operations of partners, and suppliers. The outbreak of COVID-19 forced us to modify our business practices in order to comply with state mandated requirements for safety in the workplace to ensure the health, safety and well-being of our employees.

A recession or financial market correction resulting from the lack of containment and spread of COVID-19 could impact overall technology spending, adversely affecting demand for our products, our business and the value of our common stock.

An extended period of economic disruption as a result of the COVID-19 pandemic could have a material negative impact on our business, results of operations, access to sources of liquidity and financial condition, though the full extent and duration is uncertain.

Another pandemic, epidemic, or outbreak of an infectious disease could occur in the United States or worldwide, and such an event could adversely affect our business in ways that are similar to or different from the COVID-19 pandemic. We may be unable to properly anticipate or prepare for these events and, as a result, our business may be materially adversely impacted.

It is also worth paying attention to contagious diseases of bred birds: plague, pasteurellosis (cholera), paratyphoid (salmonellosis), aspergillosis, pullorosis (white bacillary diarrhea), coccidiosis and others. For many of them, effective treatment measures have not been developed yet, so special attention should be paid to disease prevention

and compliance with sanitary and veterinary requirements. To improve safety in the poultry industry, certain measures must be taken. To protect against moving parts, all machines and equipment should be equipped with protective devices, fans should be covered with protective screens. Gloves must be worn when performing tasks that involve hand contact with birds. High standards of personal hygiene must be maintained and any injury to the body, however slight, if it comes from machinery or equipment or birds, must be treated immediately to prevent infection.

*We face significant competition, and if our competitors market their feed additives or develop their technologies more effectively than we do, our business and our ability to develop and successfully commercialize products may be adversely affected.*

 

We face substantial competition from many companies engaged in producing poultry feed additives in the United States. These competitive pressures could have a material adverse impact on our business, results of operations, or financial condition. Recently there has been an increased demand for feeds, particularly for ingredients that do not contain antibiotics.

We have been focused on conducting scientific research followed by practical testing applying technology for poultry production without using antibiotics. An organic egg was developed using our two main product candidates 'CHASIS' and 'MAGA'. Before starting to implement the program, among the arising problems were the accumulation of antibiotic residues in the final product, such as commercial eggs and egg powder, and reducing egg production. Feeding was carried out under the supervision of veterinarians under the provided scheme and accompanied by advice of IPAX specialists. Having received the egg and egg powder without residues of antibiotics and harmful substances, the effect of feed additives was studied. The conducted research was the next step towards getting the products certified and entering international markets with a qualitatively new product, the popularity, and demand for which is expanding and increasing.

Our competitors have developed, are developing, or may develop product candidates competitive with our product candidates. Any product candidates that we develop and commercialize will compete with already existing and those developed in the nearest future. We believe that a significant number of products are currently under development, and may become commercially available in the future, for the treatment of conditions for which we may attempt to develop product candidates. In particular, there is intense competition in producing antibiotic-free poultry meat. And demand for antibiotic-free products continues to increase in the U. S. We will compete with large companies that have been marketing their products for years. Moreover, there are continuously emerging new companies that develop their product candidates and enter the market.

*We may be unable to retain our future customers and to attract new customers, therefore, our business, financial condition or results of operations could suffer.*

 

Our success will depend substantially upon the retention of our future customers and ability to attract new customers. We may be unable to retain our future customers and to attract new customers if we don't provide quality poultry feed additives to the U.S. market. Our success in retaining and attracting customers will also depend on our ability to innovate successfully and promote our products rapidly. Effective company operations will result in managing their revenue cycle, increasing payment rates, and improving cash flows.

To enter and remain competitive in the market, we will need to offer a healthy, antibiotic-free product. Moreover, we will need to complete a clinical study of our product candidates to obtain authorization from the Food and Drug Administration (FDA) in the future, which will take a considerable amount of time and other sources. We may not be able to retain or attract customers if we use the wrong promotion techniques or if our pricing structure is not competitive. Our revenue depends in part upon maintaining high customer retention rates and our future growth depends on attracting new customers. If we are unable to maintain our customer retention rates, or if we are unable to attract new customers, our business, results of operations, or financial condition could be adversely impacted.

Risks Related to Our Limited Operating History, Financial Position and Capital Requirements

 

*Because we have a limited operating history, we may never generate any revenue or become profitable or, if we achieve profitability, we may not be able to sustain it.*

We were incorporated on September 20, 2021, and as a result, we have limited operating history upon which a potential investor can evaluate our prospects and the potential of our business. We have focused primarily on business planning, raising capital, and exploring marketing and distributing opportunities in North America. We intend to file an IND and we do not know if our products will succeed in clinical development or become products of commercial value. We face all the risks inherent in a new business, and there can be no assurance that we will be successful and/or profitable. Our entry into the poultry industry and our lack of a significant operating history make it difficult to evaluate the risks and uncertainties we face. Our failure to address these risks and uncertainties could cause our business results to suffer.

We do not have any products approved for sale and have not generated any revenue since our inception. If our product candidates are not successfully developed and approved, we may never generate any significant revenue. All of our products will require substantial additional development time and resources before we would be able to apply for or receive regulatory approvals and begin generating revenue from product sales. We may incur losses for the foreseeable future, and we anticipate these losses may increase substantially as we continue our development of, seek regulatory approval for, and potentially commercialize any of our product candidates and seek to identify, assess, acquire, in-license, or develop additional products.

To become and remain profitable, we must succeed in developing and eventually commercializing our product candidates that generate significant revenue. This will require us to be successful in a range of challenging activities, including obtaining regulatory approval, and marketing and selling any products for which we may obtain regulatory approval. We are only in the preliminary stages of most of these activities. We may never succeed in these activities and, even if we do, may never generate revenues that are significant enough to achieve profitability. In addition, we have not yet demonstrated an ability to successfully overcome many of the risks and uncertainties frequently encountered by companies in new and rapidly evolving fields, particularly in the inorganic products industry. Because of the numerous risks and uncertainties associated with the development of feed additives, we are unable to accurately predict the timing or amount of increased expenses or when or if, we will be able to achieve profitability. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable may have an adverse effect on the value of our company and could impair our ability to raise capital, expand our business, maintain our research and development efforts, diversify our product candidates, or even continue our operations. A decline in the value of our company could also cause you to lose all or part of your investment.

*We may be deemed to be a "shell company" and as such shareholders may not be able to rely on the provisions of Rule 144 for resale of their shares until certain conditions are met.*

We do not believe that the Company is a "shell company" as described under Rule 405 of Regulation C under the Securities Act of 1933, that has: no or nominal operations; and either (a) no or nominal assets; (b) assets consisting solely of cash and cash equivalents; or (c) assets consisting of any amount of cash and cash equivalents and nominal other assets. However, a designation as a "shell company" could result in the application of Rule 144(i), which would limit the availability of the exemption from registration provided in Rule 144 for certain shares of Company common stock and could result in certain persons affiliated with the Company being deemed "statutory underwriters under Rule 145(c). Some of the presently outstanding shares of our common stock are "restricted securities" as defined under Rule 144 promulgated under the Securities Act and may only be sold pursuant to an effective registration statement or an exemption from registration, if available. Pursuant to Rule 144, if we were designated a "shell company" as defined in Rule 405 of the Securities Act and Rule 12b-2 of the Exchange Act, one year would be required to elapse from the time, we ceased to be a "shell company" and filed a Form 8-K addressing Item 5.06 with such information as may be required in a Form 10 Registration Statement with the SEC, before our restricted shareholders could resell their holdings in reliance on Rule 144. The Form 10 information or disclosure is equivalent to the information that a company would be required to file if it were registering a class of securities on Form 10 under the Exchange Act. Under amended Rule 144, restricted or unrestricted securities that were initially issued by a reporting or non-reporting shell company, or a company that was at any time previously a reporting or non-reporting shell company, can only be resold in reliance on Rule 144 if the following conditions are met:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. The issuer of the securities that was formerly a reporting or non-reporting shell company has ceased to be a shell company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. The issuer of the securities is subject to the reporting requirements of Section 13 or 15(d) of the Exchange Act.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. The issuer of the securities has filed all reports and material required to be filed under Section 13 or 15(d) of the Exchange Act, as applicable, during the preceding twelve months (or shorter period that the Issuer was required to file such reports and materials), other than Form 8-K reports; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. At least one year has elapsed from the time the issuer filed the current Form 10 type information with the SEC reflecting its status as an entity that is not a shell company.

At the present time, we are not classified as a "shell company" under Rule 405 of the Securities Act Rule 12b-2 of the Exchange Act. However, in the event we were to be so designated, you would be unable to sell your shares under Rule 144.

 

*We will require substantial additional funding and may be unable to raise capital when needed, which would force us to delay, reduce or eliminate our product development programs or commercialization efforts and could cause our business to fail.*

Based on our current operating expenses and working capital requirements, we expect them to increase in connection with our ongoing activities, particularly as we conduct our ongoing and planned clinical trials for our product candidates and seek regulatory approval for our current product candidates and any future product candidates we may develop. In addition, our plans may change, and/or we may use our capital resources more rapidly than we currently anticipate. We presently expect that our expenses will increase in connection with our

ongoing activities to support our business operations inclusive of filing an IND and therefore we will require additional funding. Our future capital requirements will depend on many factors, including:

▪ the scope, progress, and results of our research and development processes;

▪ the costs and timing of manufacturing for current or future product candidates, including commercial-scale manufacturing, if any product candidate is approved;

▪ the costs, timing, and outcome of regulatory reviews of current or future product candidates;

▪ the scope, progress, results, costs, timing, and outcomes of any regulatory process for any of our product candidates;

▪ the timing of entering into, and the terms of, any collaboration agreements with third parties relating to any of our product candidates;

▪ any delays or cost increases that may result from the COVID-19 pandemic or any other epidemic diseases;

▪ the costs of operating, expanding, and enhancing our operations to support our clinical activities and, if our product candidates are approved, commercialization activities;

▪ our ability to achieve sufficient market acceptance, coverage, and adequate compensation from third-party payors and adequate market share and revenue for any approved products;

▪ the cost associated with being a public company, including obligations to regulatory agencies, and increased investor relations and corporate communications expenses; and

▪ the costs of additional general and administrative personnel, including accounting and finance, legal and human resources employees.

We intend to obtain additional financing for our business through public or private securities offerings, and also through entering agreements with our customers. We cannot provide any assurance that additional financing from these sources will be available on favorable terms, if at all. If we are unable to obtain adequate financing on a timely basis or on acceptable terms in the future, we would likely be required to delay, reduce or eliminate one or more of our product development activities, which could cause our business to fail.

Further, developing our product candidates and completing preclinical studies and clinical trials is a time-consuming, high-cost, and uncertain process that takes months to complete, and we may never generate the necessary data or results required to obtain regulatory approval and commercialize our product candidates. If approved, our product candidates may not achieve commercial success. Our commercial revenues, if any, will be derived from sales of products that we do not expect to be commercially available for many years, if at all. Accordingly, we will need to continue to rely on additional financing to achieve our business objectives. Adequate additional financing may not be available to us on acceptable terms, or at all.

There may also be financial problems due to financial loss or direct monetary damage associated with unforeseen payments, payment of fines, payment of additional taxes, etc. In addition, financial losses may occur in the event of a shortfall or non-receipt of funds from these provided sources, in case of non-repayment of debts, non-payment

by the buyer of the products supplied to him, a decrease in revenue due to a decrease in prices for goods and services sold. Special types of monetary damage are associated with inflation, changes in the exchange rate, additional withdrawal of funds from enterprises to the state (republican, local) budget. Along with irretrievable losses, there may also be temporary financial losses caused by the freezing of accounts, untimely disbursement of funds, and deferment of debt payments.

*We will incur increased costs associated with, and our management will need to devote substantial time and effort to, compliance with public company reporting and other requirements.*

As a public company, we incur significant legal, accounting, and other expenses. In addition, the rules and regulations of the SEC and any national securities exchange to which we may be subject in the future impose numerous requirements on public companies, including requirements relating to our corporate governance practices, with which we will need to comply. Further, we will continue to be required to, among other things, file annual, quarterly and current reports with respect to our business and operating results. Based on currently available information and assumptions, we estimate that we will incur up to approximately $25,000 in expenses in the coming year. Our management will need to devote substantial time to gaining expertise regarding operations as a public company and compliance with applicable laws and regulations, and our efforts and initiatives to comply with those requirements could be expensive.

*We will incur significant increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives.*

As a public company, we incur significant legal, accounting, and other expenses. We will be subject to the reporting requirements of the Exchange Act, which will require, among other things, that we file with the SEC annual, quarterly, and current reports with respect to our business and financial condition. We expect the rules and regulations applicable to public companies to substantially increase our legal and financial compliance costs and to make some activities more time consuming and costly. If these requirements divert the attention of our management and personnel from other business concerns, they could have a material adverse effect on our business, financial condition, and results of operations. The increased costs will decrease our net income or increase our net loss and may require us to reduce costs in other areas of our business or increase the prices of our products or services. For example, we expect these rules and regulations to make it more difficult and more expensive for us to obtain director and officer liability insurance, and we may be required to incur substantial costs to maintain the same or similar coverage. We cannot predict or estimate the amount or timing of additional costs we may incur to respond to these requirements. The impact of these requirements could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, our board committees or as executive officers.

Risks Related to Commercialization, Development and Regulatory Approval of Our Product Candidates

*Our future product candidates that will be submitted to the FDA may obtain FDA approval later in the future.*

The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign laws and regulations requires substantial time and financial resources. Failure to comply with the applicable U.S. requirements during the product development process, approval process, or after approval may subject an applicant to administrative or judicial sanctions. These sanctions could include, among other actions, the FDA's refusal to approve pending applications, withdrawal of an approval, a clinical hold, untitled or warning letters, requests for voluntary product recalls or withdrawals from the market, product seizures, total or partial suspension of production or distribution injunctions, fines, refusals of government contracts, restitution, disgorgement, or civil or criminal penalties. After conducting preclinical tests and submitting the required data, the IND automatically becomes effective 30 days after receipt by the FDA. However, FDA may not approve the application in case there are raised concerns or questions related to a proposed clinical trial, which will delay the obtaining of the approval.

*The successful commercialization of our product candidates, if approved, will depend in part on the extent to which we will manage to market our products and coordinate with our partners. This will have a direct impact on our ability to generate revenue.*

Our ability to cooperate with companies ready to integrate a feed-additives formula will have an effect on our ability to successfully commercialize our products in the future. Accordingly, we will need to successfully implement a marketing strategy for any approved product candidate. We cannot be sure that we will be able to find partners and sell our product candidates as anticipated. Once approved, we will start searching for companies for our future cooperation. However, this process is time-consuming and costly. There is no assurance that we will successfully sell our product candidates.

*We cannot be certain that we will be able to obtain regulatory approval for, or successfully commercialize, any of our current or future product candidates.*

We may not be able to develop our existing or any future product candidates. Our product candidates will require substantial additional clinical development, testing, and regulatory approval before we are permitted to commence commercialization. The clinical trials of our product candidates are, and the marketing of our product candidates will be, subject to extensive and rigorous review and regulation by numerous government authorities in the U.S., by the Food and Drug Administration particularly, if approved, market any product candidate. Before obtaining regulatory approvals for the commercial sale of any product candidate, we must demonstrate through pre-clinical testing and clinical trials that the product candidate is safe and effective for use in each target indication. This process can take a substantial amount of time and may include post-marketing studies and surveillance, which will require the expenditure of substantial resources. Of the large number of drugs in development in the U.S., only a small percentage successfully completes the FDA regulatory approval process and is commercialized. Accordingly, even if we are able to obtain the requisite financing to continue to fund our development and clinical programs, we cannot assure you that any of our product candidates will be successfully developed or commercialized. There may also be problems, that the business process is slower than planned (delay in the supply of equipment, materials, product sales, improperly planned business process without taking into account unforeseen delays).

In order to market our products in the U.S., we have to receive approval of a New Drug Application, or an NDA, for that product from the FDA, or in any foreign countries until we receive the requisite approval from such countries. Obtaining approval of an NDA is a complex, lengthy, expensive and uncertain process, and the FDA may delay, limit or deny approval of any product candidate for many reasons, including, among others:

▪ we may not obtain regulatory approvals and the subsequently comply with
appropriate federal, state, local and foreign laws and regulations;

▪ the FDA may require that we conduct additional clinical trials;

▪ we may fail to successfully submit IND and become effective;

▪ we may fail satisfactory complete an FDA pre-approval inspection of the
manufacturing facility or facilities at which the product candidate, or components thereof, are produced to assess compliance with the
FDA's cGMP requirements;

▪ the results of our clinical trials may not meet the level of statistical
or clinical significance required by the FDA for marketing approval;

▪ the FDA may not approve the manufacturing processes or facilities of third-party
manufacturers with which we contract; or

▪ the FDA may change its approval policies or adopt new regulations.

Any of these factors, many of which are beyond our control, could jeopardize our ability to obtain regulatory approval for and successfully market any product candidate. Moreover, because a substantial portion of our business is or may be dependent upon our product candidates, any such setback in our pursuit of initial or additional regulatory approval would have a material adverse effect on our business and prospectus.

*We face significant competition, and if our competitors develop technologies or product candidates more rapidly than we do or their technologies are more effective, our business and our ability to develop and successfully commercialize products may be adversely affected.*

Our competitors may develop their product candidates and technology faster and more efficiently than we do which will result in our failure to market our product candidates as anticipated. Our competitors have developed, are developing or may develop products, product candidates and processes competitive with our product candidates.

Any product candidates that we successfully develop and commercialize will compete with existing products and new products that may become available in the future. We believe that a significant number of products are currently under development, and may become commercially available in the future, for the treatment of conditions for which we may attempt to develop product candidates. There are a great number of companies in the U.S. who offer antibiotic-free poultry products. Our competitors include larger companies producing antibiotic-free meat products. Moreover, we may also compete with those companies, who are just developing their feed additives and preparing to enter the U.S. market. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies.

Many of our competitors have significantly greater financial, technical, manufacturing, marketing, sales and supply resources or experience than we do. If we successfully obtain approval for any product candidate, we will face competition based on many different factors, including the safety and effectiveness of our products, the ease with which our products can be administered, the timing and scope of regulatory approvals for these products, the availability and cost of manufacturing, marketing and sales capabilities, price, reimbursement coverage and patent position. Competitive products approaches may make any products we develop obsolete or noncompetitive before we recover the expense of developing and commercializing our product candidates. Our competitors may have greater resources than we do, allowing them to advance faster than we are able to.

*We currently have no marketing and sales organization and have no experience as a company in commercializing products, and we may need to invest significant resources to develop these capabilities. If we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell our products, we may not be able to generate product revenue.*

We have no internal sales, marketing, or distribution capabilities, nor have we commercialized a product. If any of our product candidates ultimately receives regulatory approval, we must build a marketing and sales organization with technical expertise and supporting distribution capabilities to commercialize each such product in major markets, which will be expensive and time consuming. Alternatively, we may need to collaborate with third parties that have direct sales forces and established distribution systems, in lieu of or to augment our own sales force and distribution systems. We have no prior experience as a company in the marketing, sale and distribution of poultry additives and there are significant risks involved in building and managing of a sales organization, including our ability to hire, retain and incentivize qualified individuals, generate sufficient sales leads, provide adequate training to sales and marketing personnel and effectively manage a geographically dispersed sales and marketing team. Any failure or delay in the development of our internal sales, marketing and distribution capabilities would adversely impact the commercialization of these products. We may not be able to enter into collaborations or hire consultants or external service providers to assist us in sales, marketing and distribution functions on acceptable financial terms, or at all. In addition, our product revenues and our profitability, if any, may be lower if we rely on third parties for these functions than if we were to market, sell and distribute any products that we develop ourselves. We likely will have little control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market our products effectively. If we are not successful in commercializing our products, either on our own or through arrangements with one or more third parties, we may not be able to generate any future product revenue and we would incur significant additional losses.

*Our future growth may depend, in part, on our ability to operate in foreign markets, where we would be subject to additional regulatory burdens and other risks and uncertainties.*

Our future growth may depend, in part, on our ability to develop and commercialize our product candidates in foreign markets. We are not permitted to market or promote any of our product candidates before we receive regulatory approval from applicable regulatory authorities in foreign markets, and we may never receive such regulatory approvals for any of our product candidates. To obtain separate regulatory approval in many other countries we must comply with numerous and varying regulatory requirements regarding safety and efficacy and governing, among other things, commercial sales, pricing and distribution of our product candidates. If we obtain regulatory approval of our product candidates and ultimately commercialize our products in foreign markets, we would be subject to additional risks and uncertainties, including:

&nbsp;&nbsp;&nbsp;&nbsp;▪ reduced protection for intellectual property rights;

&nbsp;&nbsp;&nbsp;&nbsp;▪ the existence of additional third-party patent rights of potential relevance
to our business;

&nbsp;&nbsp;&nbsp;&nbsp;▪ pricing pressure from vaccine procurement organizations;

&nbsp;&nbsp;&nbsp;&nbsp;▪ foreign compensation, pricing and insurance regimes;

&nbsp;&nbsp;&nbsp;&nbsp;▪ unexpected changes in tariffs, trade barriers and regulatory requirements;

&nbsp;&nbsp;&nbsp;&nbsp;▪ economic weakness, including inflation, or political instability in particular
foreign economies and markets;

&nbsp;&nbsp;&nbsp;&nbsp;▪ differing regulatory requirements with respect to manufacturing of vaccine
products; compliance with export control and import laws and regulations;

&nbsp;&nbsp;&nbsp;&nbsp;▪ foreign currency fluctuations, which could result in increased operating
expenses and reduced revenues, and other obligations incident to doing business in another country;

&nbsp;&nbsp;&nbsp;&nbsp;▪ compliance with tax, employment, immigration and labor laws for employees
living or traveling abroad;

&nbsp;&nbsp;&nbsp;&nbsp;▪ production shortages resulting from any events affecting raw material supply
or manufacturing capabilities abroad; and

▪ business interruptions resulting from geopolitical actions, including war and terrorism, or natural disasters including earthquakes, typhoons, floods and fires.

*MAGA and CHASIS may prove to be difficult to effectively commercialize as planned.*

Various commercial, regulatory, and manufacturing factors may impact our ability to maintain or grow revenues from sales of MAGA and CHASIS. Among the difficulties we may meet are

▪ our inability to effectively transfer and scale manufacturing as needed
to maintain an adequate commercial supply of these products;

▪ our inability to adequately market and increase sales of any of these products;

▪ our inability to effectively identify and align with commercial partners
outside the U.S., or the inability of those selected partners to gain the required regulatory, compensation, and other approvals needed
to enable commercial success of our product candidates.

*Any third-party manufacturers we engage are subject to various governmental regulations, and we may incur significant expenses to comply with, and experience delays in, our product commercialization as a result of these regulations.*

 

In future we will engage companies in order to sell our feed additives formula and market our products. This will include documents preparation, testing, quality assurance, labeling, packaging, sterilization, storage and shipping of product candidates. Any inspection by the FDA could lead to additional compliance requests that could cause delays in our product commercialization. Failure to comply with applicable FDA requirements, or later discovery of previously unknown problems with the manufacturing processes and facilities of third-party manufacturers we engage, including the failure to take satisfactory corrective actions, can result in, among other things:

&nbsp;&nbsp;&nbsp;&nbsp;▪ the FDA's refusal to grant pending future clearance or pre-market
approval;

&nbsp;&nbsp;&nbsp;&nbsp;▪ administrative or judicially imposed sanctions;

&nbsp;&nbsp;&nbsp;&nbsp;▪ injunctions or the imposition of civil penalties;

&nbsp;&nbsp;&nbsp;&nbsp;▪ recall or seizure of the product in question;

&nbsp;&nbsp;&nbsp;&nbsp;▪ total or partial suspension of production or distribution;

&nbsp;&nbsp;&nbsp;&nbsp;▪ withdrawal or suspension of marketing clearances or approvals;

&nbsp;&nbsp;&nbsp;&nbsp;▪ clinical holds;

&nbsp;&nbsp;&nbsp;&nbsp;▪ refusal to permit the export of the product in question;

&nbsp;&nbsp;&nbsp;&nbsp;▪ warning letters; and

▪ criminal prosecution.

Any of these actions, in combination or alone, could prevent us from marketing, distributing or selling our products, and would likely harm our business.

In addition, a product defect or regulatory violation could lead to a government-mandated or voluntary recall by us. We believe the FDA would request that we initiate a voluntary recall if a product was defective or presented a risk of injury or gross deception. Regulatory agencies in other countries have similar authority to recall drugs or devices because of material deficiencies or defects in design or manufacture that could endanger health. Any recall would divert our management attention and financial resources, expose us to product liability or other claims, and harm our reputation with customers.

*Even if we, or our collaborators, obtain marketing approvals for our product candidates, the terms of approvals and ongoing regulation of our products may limit how we or they market our products, which could materially impair our ability to generate revenue.*

Even if we receive regulatory approval for a product candidate, this approval may carry conditions that limit the market for the product or put the product at a competitive disadvantage relative to alternative therapies. For instance, a regulatory approval may limit the indicated uses for which we can market a product or the patient population that may utilize the product or may be required to carry a warning in its labeling and on its packaging. Products with black box warnings are subject to more restrictive advertising regulations than products without such warnings. These restrictions could make it more difficult to market any product candidate effectively. Accordingly, assuming we, or our collaborators, receive marketing approval for one or more of our product candidates, we, and our collaborators expect to continue to expend time, money and effort in all areas of regulatory compliance.

*We rely on third parties to conduct our clinical trials and perform data collection and analysis, which may result in costs and delays that prevent us from successfully commercializing product candidates.*

We may use medical institutions, clinical investigators, contract research organizations, contract laboratories, and collaborators to perform data collection and analysis and others to carry out our clinical trials. Our development activities or clinical trials conducted in reliance on third parties may be delayed, suspended, or terminated if:

&nbsp;&nbsp;&nbsp;&nbsp;▪ the third parties do not successfully carry out their contractual duties
or fail to meet regulatory obligations or expected deadlines;

&nbsp;&nbsp;&nbsp;&nbsp;▪ we replace a third party; or

&nbsp;&nbsp;&nbsp;&nbsp;▪ the quality or accuracy of the data obtained by third parties is compromised
due to their failure to adhere to clinical protocols, regulatory requirements, or for other reasons.

In addition, our or a third party's failure to execute on our manufacturing requirements on commercially reasonable terms and in compliance with FDA or other regulatory requirements could adversely affect our business in a number of ways, including:

&nbsp;&nbsp;&nbsp;&nbsp;▪ a delay in submitting regulatory applications, or receiving marketing approvals,
for our product candidates;

&nbsp;&nbsp;&nbsp;&nbsp;▪ subjecting third-party manufacturing facilities or our potential future
manufacturing facilities to additional inspections by regulatory authorities;

&nbsp;&nbsp;&nbsp;&nbsp;▪ an inability to initiate clinical trials of our product candidates under
development;

▪ in the event of approval to market and commercialize our product candidates, an inability to meet commercial demands for our product candidates or any other future product candidates.

Third party performance failures may increase our development costs, delay our ability to obtain regulatory approval, and delay or prevent the commercialization of our product candidates. While we believe that there are numerous alternative sources to provide these services, in the event that we seek such alternative sources, we may not be able to enter into replacement arrangements without incurring delays or additional costs.

Risks Related to Our Structure, Organization, and Operation

 

*Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and stock price.*

The global credit and financial markets continue to experience extreme volatility and disruptions, including severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic stability. There can be no assurance that further deterioration in credit and financial markets and confidence in economic conditions will not occur. Our general business strategy may be adversely affected by any such economic downturn, volatile business environment or continued unpredictable and unstable market conditions. If the current equity and credit markets deteriorate, it may make any necessary debt or equity financing more difficult, more costly and more dilutive. Failure to secure any necessary financing in a timely manner and on favorable terms could have a material adverse effect on our growth strategy, financial performance and stock price and could require us to delay or abandon clinical development plans.

 

*If we fail to establish and maintain proper internal controls, our ability to produce accurate financial statements or comply with applicable regulations could be impaired.*

Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Pursuant to Section 404 of the Sarbanes-Oxley Act, our management conducted an assessment of the effectiveness of our internal controls over financial reporting for the period ended October 31, 2022 and concluded that such control was effective. The rules governing the standards that must be met for our management to assess our internal control over financial reporting are complex and require significant documentation, testing and possible remediation. To comply with the requirements of being a reporting company under the Exchange Act, we may need to implement additional financial and management controls, reporting systems and procedures; and hire additional accounting and finance staff. If we or, if required, our auditors are unable to conclude that our internal control over financial reporting is effective, investors may lose confidence in our financial reporting and the trading price of our common stock may decline.

We cannot assure you that there will not be material weaknesses or significant deficiencies in our internal control over financial reporting in the future. Any failure to maintain internal control over financial reporting could severely inhibit our ability to accurately report our financial condition, results of operations or cash flows. If we are unable to conclude that our internal control over financial reporting is effective, or if our independent registered public accounting firm determines we have a material weakness or significant deficiency in our internal control over financial reporting once that firm begin its Section 404 reviews, investors may lose confidence in the accuracy and completeness of our financial reports, the market price of our common stock could decline, and we could be subject to sanctions or investigations by the SEC or other regulatory authorities. Failure to remedy any material weakness in our internal control over financial reporting, or to implement or maintain other effective control systems required of public companies, could also restrict our future access to the capital markets.

*Because our sole officer and director will only be devoting limited time to our operations, our operations may be sporadic which may result in periodic interruptions or suspensions of operations. This activity could prevent us from attracting enough customers and result in a lack of revenues which may cause us to cease operations.* 

Oleg Bilinski, our sole officer and director will only be devoting limited time to our operations. Even if our sole officer and director were to devote approximately 40 hours of his time to our operations per week, there would be a possibility that our operations may be sporadic and occur because all this time could be not enough for our business. As a result, operations may be periodically interrupted or suspended which could result in a lack of revenues and a possible cessation of operations.

Risks Related to Our Intellectual Property

*We might be unable to obtain and maintain patent protection for our product candidates, and our competitors could develop and commercialize products similar or identical to ours.*

Our ability to successfully commercialize our product candidates may be adversely affected if we fail to obtain and maintain patent protection in the United States and other countries with respect to our product candidates and other technologies we may develop. Animal feed additives companies devote significant financial resources to discovering, developing, or licensing their products that could make our product candidates obsolete. Our competitors may obtain patent protection, receive FDA approval, and commercialize medicines before us. Other companies are or may become engaged in the testing of product candidates that may compete with the product candidates we are developing.

The patent prosecution process is expensive, time-consuming, and complex, and we or our licensors may not be able to file, prosecute or maintain all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output in time to obtain patent protection.

In addition, our ability to obtain and maintain valid and enforceable patents depends on whether the differences between our inventions and the prior art allow our inventions to be patentable over the prior art. Also, we cannot assess the full scale of the feed additives companies that are currently on the U.S. market. Therefore, we cannot be certain that we or our licensors were the first to make the inventions claimed in any of our owned or licensed

patents or pending patent applications, or that we or our licensors were the first to file for patent protection of such inventions. This may result in us needing to obtain additional licenses, which could have a financial impact, or ceasing development of our candidates if not able to obtain additional necessary licenses. The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has been the subject of much litigation in recent years. As a result, the issuance, scope, validity, enforceability, and commercial value of our patent rights are highly uncertain. Our patent applications may not result in patents being issued which protect our product candidates or proprietary technologies we may develop or which effectively prevent others from commercializing competitive technologies and products.

Moreover, the claim coverage in a patent application can be significantly reduced before the patent is granted. Even if our patent applications are issued as patents, they may not be issued in a form that will provide us with any meaningful protection, prevent competitors or other third parties from competing with us or otherwise provide us with any competitive advantage. Any patents issued from our patent applications may be challenged, narrowed, circumvented, or invalidated by third parties. Even if a patent is granted, our competitors or other third parties may be able to circumvent the patent by developing similar or alternative technologies or products in a non-infringing manner which could materially adversely affect our business, financial condition, results of operations and prospects. In addition, given the amount of time required for the development, testing and regulatory review of our product candidates, patents protecting the product candidates might expire before or shortly after such product candidates are commercialized. As a result, our intellectual property may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.

The issuance of a patent is not conclusive as to its inventorship, scope, validity, or enforceability and our patents may be challenged in the courts or patent offices in the United States and abroad. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate or render unenforceable, our patent rights, allow third parties to commercialize our therapeutic programs and other proprietary technologies we may develop and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. Such proceedings also may result in substantial cost and require significant time from our scientists and management, even if the eventual outcome is favorable to us.

Moreover, some of our owned and in-licensed patent rights may in the future be co-owned with third parties. If we are unable to obtain an exclusive license to any such third-party co-owners' interest in such patent rights, such co-owners may be able to license their rights to other third parties, including our competitors, and our competitors could market competing products and technology. In addition, we may need the cooperation of any such co-owners of such patent rights in order to enforce such patent rights against third parties, and such cooperation may not be provided to us. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects.

*We may not be able to adequately protect our proprietary product candidates, and our competitors may be able to offer similar products which would harm our competitive position.*

 

Our success depends upon our product candidates. We rely or may rely primarily on copyright, service mark, confidentiality procedures and contractual provisions to establish and protect our proprietary rights. As part of our confidentiality procedures, we may enter non-disclosure agreements with our employees and consultants. Despite these precautions, third parties could copy or otherwise obtain and use our product candidates without authorization or develop similar ones independently. We cannot assure you that the protection of our proprietary rights will be adequate or that our competitors will not independently develop, duplicate our products and services.

Risks Related to This Offering and Our Common Stock

*The proceeds from this offering may be insufficient to achieve substantial revenues and profitable operations and we may need personal funds of the Director of the Company.* 

Currently we have not enough operating funds required for completing our intended operations. We need the proceeds from this offering to start our operations as described in the "Plan of Operation" section of this prospectus. As of April 30, 2022, we had cash in the amount of 4,500.75 and liabilities of $2,950.

The proceeds of this offering may not be sufficient for us to achieve substantial revenues and profitable operations. We need additional funds to achieve a sustainable sales level where ongoing operations can be funded out of revenues. There is no assurance that any additional financing will be available or if available, on terms that will be acceptable to us. We require minimum funding of approximately $25,000 to conduct our proposed operations for a period of one year.

If we are successful in raising the funds from this offering, we plan to commence activities to continue our operations and further develop existing and new product candidates. We cannot provide investors with any assurance that we will be able to raise sufficient funds to continue our business plan according to our plan of operations.

If we are not successful in raising funds from this offering, Mr. Bilinski formally agreed to advance funds to the Company to loan the Company the principal sum of $60,000 for business development under a Loan Agreement. The Loan Agreement is non-binding and discretionary, bears no interest, is unsecured, and is due and payable on or before December 2, 2028.

If we are successful in raising the funds from this offering, we plan to commence activities to continue our operations and further develop existing and new product candidates. We cannot provide investors with any assurance that we will be able to raise sufficient funds to continue our business plan according to our plan of operations. In this situation, it is worth considering innovation risk (related to the fact that an innovation, on the development of which significant funds were spent, will not find demand in the market).

*We are an "emerging growth company" under the JOBS Act, and we cannot be certain if the reduced disclosure requirements applicable to emerging growth companies will make our common stock less attractive to investors.*

We qualify as an "emerging growth company" under the JOBS Act. As a result, we are permitted to, and intend to, rely on exemptions from certain disclosure requirements. For so long as we are an emerging growth company, we will not be required to:

- have an auditor report on our internal controls over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act;

- provide an auditor attestation with respect to management's report on the effectiveness of our internal controls over financial reporting;

- comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor's report providing additional information about the audit and the financial statements (i.e., an auditor discussion and analysis);

- submit certain executive compensation matters to shareholder advisory votes, such as "say-on-pay" and "say-on-frequency;" and

- disclose certain executive compensation related items such as the correlation between executive compensation and performance and comparisons of the Chief Executive's compensation to median employee compensation.

In addition, Section 107 of the JOBS Act also provides that an emerging growth company can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. In other words, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to take advantage of the benefits of this extended transition period. Our financial statements may therefore not be comparable to those of companies that comply with such new or revised accounting standards.

We will remain an "emerging growth company" for up to five years, or until the earliest of

(i) the last day of the first fiscal year in which our total annual gross revenues is $1 billion,

(ii) the date that we become a "large accelerated filer" as defined in Rule 12b-2 under the Securities Exchange Act of 1934, which would occur if the market value of our ordinary shares that is held by non-affiliates is $700 million as of the last business day of our most recently completed second fiscal quarter or (iii) the date on which we have issued more than $1 billion in non-convertible debt during the preceding three-year period. Until such time, however, we cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile. Notwithstanding the above, we are also currently a "smaller reporting company", meaning that we are not an investment company, an asset-backed issuer, or a majority-owned subsidiary of a parent company that is not a smaller reporting company and have a public float of less than $75 million and annual revenues of less than $50 million during the most recently completed fiscal year. In the event that we are still considered a "smaller reporting company", at such time are we cease being an "emerging growth company", the disclosure we will be required to provide in our SEC filings will increase but will still be less than it would be if we were not considered either an "emerging growth company" or a "smaller reporting company". Specifically, similar to "emerging growth companies", "smaller reporting companies" are able to provide simplified executive compensation disclosures in their filings; are exempt from the provisions of Section 404(b) of the Sarbanes-Oxley Act requiring that independent registered public accounting firms provide an attestation report on the effectiveness of internal control over financial reporting; and have certain other decreased disclosure obligations in their SEC filings, including, among other things, being required to provide only two years of audited financial statements in annual reports. Decreased disclosures in our SEC filings due to our status as an "emerging growth company" or "smaller reporting company" may make it harder for investors to analyze the Company's results of operations and financial prospects.

*We are selling this offering without an underwriter and may be unable to sell any shares.* 

This offering is self-underwritten, that is, we are not going to engage the services of an underwriter to sell the shares; we intend to sell our shares through our President, Oleg Bilinski, who will receive no commissions. There is no guarantee that he will be able to sell any of the shares. Unless he is successful in receiving the proceeds in the amount of $100,000 from this offering, we may have to seek alternative financing to implement our business plan.

*We are not required to raise a minimum amount in this Offering.* 

We do not have a minimum amount we must raise in order to accept proceeds in this offering. We may only raise a minimum of capital, which would leave us with insufficient capital to implement our business plan, which may result in a complete loss of your investment in the Company unless we are able to raise the required capital from alternative sources. We cannot assure you that alternative capital or financing would be available.

*Due to the lack of a trading market for our securities, you may have difficulty selling any shares you purchase in this offering.* 

We are not registered on any market or public stock exchange. There is presently no demand for our common stock and no public market exists for the shares being offered in this prospectus. We plan to contact a market maker immediately following the completion of the offering and apply to have the shares quoted on the Over-the-Counter Board ("OTCQB"). The OTCQB is a regulated quotation service that displays real-time quotes, last sale prices and volume information in over-the-counter securities. The OTCQB is not an issuer listing service, market or exchange. Although the OTCQB does not have any listing requirements, to be eligible for quotation on the OTCQB, issuers must remain current in their filings with the SEC or applicable regulatory authority. If we are not able to pay the expenses associated with our reporting obligations, we will not be able to apply for quotation on the OTC Board. Market makers are not permitted to begin quotation of a security whose issuer does not meet this filing requirement. Securities already quoted on the OTCQB that become delinquent in their required filings will be removed following a 30 to 60-day grace period if they do not make their required filing during that time. We cannot guarantee that our application will be accepted or approved, and our stock quoted for sale. As of the date of this filing, there have been no discussions or understandings between Mag Magna Cor. and anyone acting on our behalf, with any market maker regarding participation in a future trading market for our securities. If no market is ever developed for our common stock, it will be difficult for you to sell any shares you purchase in this offering.

In such a case, you may find that you are unable to achieve any benefit from your investment or liquidate your shares without considerable delay, if at all. In addition, if we fail to have our common stock quoted on a public trading market, your common stock will not have a quantifiable value and it may be difficult, if not impossible, to ever resell your shares, resulting in an inability to realize any value from your investment.

*Our stock price may be volatile, and purchasers of our common stock may incur substantial losses.*

 

Our stock price is likely to be volatile. The stock market in general and the stock market for stock of pharmaceutical companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, investors may not be able to sell their common stock at or above the initial public offering price. If our common stock is approved for trading or quotation, the market price of our common stock is likely to be highly volatile and could fluctuate widely in price in response to various factors, many of which are beyond our control, including the following:

&nbsp;&nbsp;&nbsp;&nbsp;▪ results of our preclinical studies and clinical trials, and the results
of trials of our competitors or those of other companies in our market sector;

&nbsp;&nbsp;&nbsp;&nbsp;▪ our ability to enroll subjects in our future clinical trials;

&nbsp;&nbsp;&nbsp;&nbsp;▪ regulatory developments in the United States and foreign countries;

&nbsp;&nbsp;&nbsp;&nbsp;▪ regulatory approval of our product candidates, or limitations to specific
label indications or target populations for its use, or changes or delays in the regulatory review process;

&nbsp;&nbsp;&nbsp;&nbsp;▪ changes in the structure of healthcare payment systems;

&nbsp;&nbsp;&nbsp;&nbsp;▪ the success or failure of our efforts to develop, acquire or license additional
vaccine candidates;

&nbsp;&nbsp;&nbsp;&nbsp;▪ innovations, clinical trial results, product approvals and other developments
regarding our competitors;

&nbsp;&nbsp;&nbsp;&nbsp;▪ manufacturing, supply or distribution delays or shortages;

&nbsp;&nbsp;&nbsp;&nbsp;▪ any changes to our relationship with any manufacturers, suppliers, collaborators
or other strategic partners;

&nbsp;&nbsp;&nbsp;&nbsp;▪ achievement of expected product sales and profitability;

&nbsp;&nbsp;&nbsp;&nbsp;▪ variations in our financial results or those of companies that are perceived
to be similar to us;

&nbsp;&nbsp;&nbsp;&nbsp;▪ market conditions in the pharmaceutical sector;

&nbsp;&nbsp;&nbsp;&nbsp;▪ trading volume of our common stock;

&nbsp;&nbsp;&nbsp;&nbsp;▪ sales of our common stock;

&nbsp;&nbsp;&nbsp;&nbsp;▪ an inability to obtain additional funding;

&nbsp;&nbsp;&nbsp;&nbsp;▪ general economic, industry and market conditions other events or factors,
many of which are beyond our control;

&nbsp;&nbsp;&nbsp;&nbsp;▪ additions or departures of key personnel;

&nbsp;&nbsp;&nbsp;&nbsp;▪ regulatory developments;

&nbsp;&nbsp;&nbsp;&nbsp;▪ changes in our capital structure, such as future issuances of securities
and the incurrence of additional debt; and

▪ changes in accounting standards, policies, guidelines, interpretations or principles.

In addition, in the past, stockholders have initiated class action lawsuits against pharmaceutical companies following periods of volatility in the market prices of these companies' stock. Such litigation, if instituted against us, could cause us to incur substantial costs and divert our management's attention and resources, which could have a material adverse effect on our business, financial condition and results of operations.

We may also have risks associated with the possibility of losses in the sale of securities or other goods due to a change in the assessment of their quality and use value. These may include:

a). possible losses caused by the inability to buy or sell an asset in the required quantity in a sufficiently short period of time due to deteriorating market conditions;

b). the possibility of a shortage of cash or highly liquid assets to fulfill obligations to counterparties.<br> Risks associated with capital investment (investment risks) are divided into:<br> - the risk of lost profits;

- the risk of a decrease in profitability;

- the risk of direct financial losses.

*The regulation of penny stocks by the SEC and FINRA may discourage the tradability of the Company's securities.* 

The shares being offered are defined as a penny stock under the Securities and Exchange Act of 1934, as amended, and rules of the Commission. The Exchange Act and such penny stock rules generally impose additional sales practice and disclosure requirements on broker-dealers who sell our securities to persons other than certain accredited investors who are, generally, institutions with assets in excess of $5,000,000 or individuals with net worth in excess of $1,000,000 or annual income exceeding $200,000 ($300,000 jointly with spouse), or in transactions not recommended by the broker-dealer. For transactions covered by the penny stock rules, a broker dealer must make certain mandated disclosures in penny stock transactions, including the actual sale or purchase price and actual bid and offer quotations, the compensation to be received by the broker-dealer and certain associated persons, and deliver certain disclosures required by the Commission. Consequently, the penny stock rules may make it difficult for you to resell any shares you may purchase, if at all.

*We do not currently intend to pay dividends on our common stock; any return on investment may be limited to the value of our common stock.* 

We do not currently anticipate paying cash dividends in the foreseeable future. The payment of dividends on our common stock will depend on earnings, financial condition and other business and economic factors affecting us when our Board of Directors may consider it relevant. Our current intention is to apply net earnings, if any, in the foreseeable future to the development of our business and to increase our working capital. There can be no assurance that we will ever have sufficient earnings to declare and pay cash dividends to the holders of our common stock, and in any event, a decision to declare and pay dividends is at the sole discretion of our Board. If we do not pay dividends, our common stock may be less valuable because a return on your investment will only occur if its stock price appreciates.

The company may also have interest risks (the risk of losses by commercial banks, credit institutions, investment institutions as a result of an increase in interest rates paid by them on attracted funds over the rates on loans granted). Interest risks also include the risks of losses that investors may incur due to changes in dividends on shares, interest rates on the market for bonds, certificates and other securities. And the risk of bankruptcy (danger resulting from the wrong choice of capital investment, the complete loss of the entrepreneur's own capital and his inability to pay off his obligations).

**SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS**

This prospectus contains forward-looking statements. All statements other than statements of historical facts contained in this prospectus, including statements regarding our future results of operations and financial position, business strategy, research and development plans, the anticipated timing, costs, design and conduct of our ongoing and planned studies for our product candidates, the timing and likelihood of regulatory filings and approvals for our product candidates, our ability to commercialize our product candidates, if approved, the impact of COVID-19 on our business, the pricing and compensation of our product candidates, if approved, the potential to develop future product candidates, the potential benefits of strategic collaborations and our intent to enter into any strategic arrangements, the timing and likelihood of success, plans and objectives of management for future operations, and future results of anticipated product development efforts, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.

In some cases, you can identify forward-looking statements by terms such as "anticipate", "believe", "plan", "expect", "future", "intend", "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this prospectus are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements speak only as of the date of this prospectus and are subject to a number of risks, uncertainties and assumptions described under the sections titled "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in this prospectus. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking statements

as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties. Except as required by applicable law, we undertake no obligation to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. You should, however, review the factors and risks we describe in the reports we will file from time to time with the SEC after the date of this prospectus. See the section titled "Where You Can Find More Information."

In addition, statements that "we believe" and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this prospectus, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and you are cautioned not to rely unduly upon them.

**USE OF PROCEEDS**

Our offering is being made on a self-underwritten and "best-efforts" basis and we require minimum funding of approximately $25,000 to conduct our proposed operations for a period of one year. The offering price per share is $0.025. The following table sets forth the uses of proceeds assuming the sale of 25%, 50%, 75% and 100%, respectively, of the securities offered for sale by the Company. There is no assurance that we will raise the full $100,000 as anticipated and there is no guarantee that we will receive any proceeds from the offering.

---

| | | | | |
|:---|:---|:---|:---|:---|
| *Description* | **If 25% shares sold** | **If 50% shares sold** | **If 75% shares sold** | **If 100% shares sold** |
| *Description* | *Fees* | *Fees* | *Fees* | *Fees* |
| ***Gross proceeds*** | **$25000** | **$50000** | **$75000** | **$100000** |
| *Offering expenses* | $8000 | $8000 | $8000 | $8000 |
| ***Net proceeds*** | **$17000** | **$42000** | **$67000** | **$92000** |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| *SEC reporting and compliance* | $10000 | $10000 | $10000 | $10000 |
| *Distribution Expenses* | 3000 | $3000 | $3500 | $4500 |
| *Professional Equipment/Software* | 4000 | $5000 | $5500 | $7000 |
| *Payment for certification(s)/ permit(s)* | - | $4000 | $5000 | $6000 |
| *Inventories* | - | $3000 | $5500 | $7000 |
| *Marketing* | - | $7000 | $17500 | $37500 |
| *Sales* | - | $10000 | $20000 | $30000 |

---

The above figures represent only estimated costs for the next year. Funds may be allocated in differing quantities should the Company determine at a later date it would be in the Company's best interests. The Company estimates the costs of this offering at about $8,000. All expenses incurred in this offering are being paid for by the Company. The Company will utilize offering proceeds from this offering to pay for any offering expenses however, the Company may also elect to use available existing cash on hand to pay for any offering expenses.

**DETERMINATION OF OFFERING PRICE**

The offering price of the shares has been determined arbitrarily by us. The price does not bear any relationship to our assets, book value, earnings, or other established criteria for valuing a privately held company. In determining the number of shares to be offered and the offering price, we took into consideration our cash on hand and the amount of money we would need to implement our business plan. Accordingly, the offering price should not be considered an indication of the actual value of the securities.

**DIVIDEND POLICY**

We have never declared or paid, and do not anticipate declaring or paying, in the foreseeable future, any cash dividends on our capital stock. We currently intend to retain all available funds and any future earnings to support our operations and finance the growth and development of our business. Any future determination related to our dividend policy will be made at the discretion of our board of directors and will depend upon, among other factors, our results of operations, financial condition, capital requirements, contractual restrictions, business prospects and other factors our board of directors may deem relevant.

**CAPITALIZATION**

The following table sets forth our capitalization as of October 31, 2022:

---

| | |
|:---|:---|
|  | &nbsp;&nbsp;October 31, 2022 |
| &nbsp;&nbsp;Loan payable from related parties | &nbsp;&nbsp;$16135 |
| &nbsp;&nbsp;*Stockholder's deficit:* |  |
| &nbsp;&nbsp;Common stock | &nbsp;&nbsp;$4500 |
| &nbsp;&nbsp;Accumulated deficit | &nbsp;&nbsp;($6894) |
| &nbsp;&nbsp;Total stockholders' equity | &nbsp;&nbsp;($2393) |
| &nbsp;&nbsp;Total capitalization | &nbsp;&nbsp;($2393) |

---

**DILUTION**

If you purchase shares in this offering, your interest will be diluted to the extent of the difference between the public offering price per share of common stock and warrant and the net tangible book value per share of our common stock after this offering. As of October 31, 2022, the historical net tangible book value was ($11,629.47), or approximately $0.00 per share. Historical net tangible book value per share of common stock is equal to our total tangible assets fewer total liabilities, divided by the number of shares of common stock outstanding as of October 31, 2022. "Net tangible book value" is total assets minus the sum of liabilities and intangible assets. "Net tangible book value per share" is net tangible book value divided by the total number of shares of common stock outstanding.

Assuming completion of the offering, there will be up to 8,500,000 common shares outstanding. The following table illustrates the per common share dilution that may be experienced by investors at various funding levels.

The dilution information set forth in the table above is illustrative only and will be adjusted based on the actual public offering price and other terms of this offering determined at pricing.

If we issue any additional shares in connection with outstanding options or warrants, there will be additional dilution.

---

| | | | | |
|:---|:---|:---|:---|:---|
| &nbsp;&nbsp;Percent of Shares Sold from Maximum Offering Available | 25% | 50% | 75% | 100% |
| &nbsp;&nbsp;Offering price per share | $0.03 | $0.03 | $0.03 | $0.03 |
| &nbsp;&nbsp;Post offering net tangible book value | ($3629) | $21371 | $46371 | $71371 |
| &nbsp;&nbsp;Post offering net tangible book value per share | $0.00 | $0.00 | $0.01 | $0.01 |
| &nbsp;&nbsp;Pre-offering net tangible book value per share | 0.00 | 0.00 | 0.00 | 0.00 |
| &nbsp;&nbsp;Increase (Decrease) in net tangible book value per share after offering | $0.00 | $0.01 | $0.01 | $0.01 |
| &nbsp;&nbsp;Dilution per share | $0.03 | $0.02 | $0.02 | $0.02 |
| &nbsp;&nbsp;% dilution | 102.64% | 86.85% | 75.27% | 66.41% |
| &nbsp;&nbsp;Capital contribution by purchasers of shares | $25000 | $50000 | $75000 | $100000 |
| &nbsp;&nbsp;Capital Contribution by existing stockholders | $4500 | $4500 | $4500 | $4500 |
| &nbsp;&nbsp;Percentage capital contributions by purchasers of shares | 84.75% | 91.74% | 94.34% | 95.69% |
| &nbsp;&nbsp;Percentage capital contributions by existing stockholders | 15.25% | 8.26% | 5.66% | 4.31% |
| &nbsp;&nbsp;Gross offering proceeds | $25000 | $50000 | $75000 | $100000 |
| &nbsp;&nbsp;Anticipated net offering proceeds | $17000 | $42000 | $67000 | $92000 |
| &nbsp;&nbsp;Number of shares after offering held by public investors | 1000000 | 2000000 | 3000000 | 4000000 |
| &nbsp;&nbsp;Total shares issued and outstanding | 5500000 | 6500000 | 7500000 | 8500000 |
| &nbsp;&nbsp;Purchasers of shares percentage of ownership after offering | 18.18% | 30.77% | 40.00% | 47.06% |
| &nbsp;&nbsp;Existing stockholders' percentage of ownership after offering | 81.82% | 69.23% | 60.00% | 52.94% |

---

**MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS**

*The following discussion and analysis should be read in conjunction with our financial statements and related notes included elsewhere in this prospectus. This discussion and analysis and other parts of this prospectus contain forward-looking statements based upon current beliefs, plans and expectations that involve risks, uncertainties and assumptions, such as statements regarding our plans, objectives, expectations, intentions and projections. Our actual results and the timing of selected events could differ materially from those anticipated in these forward-looking statements as a result of several factors, including those set forth in the section titled "Risk Factors" and elsewhere in this prospectus. You should carefully read the "Risk Factors" section of this prospectus to gain an understanding of the important factors that could cause actual results to differ materially from our forward-looking statements. Please also see the section titled "Special Note Regarding Forward-Looking Statements."*

**Overview**

Mag Magna Corp is a Wyoming company incorporated on September 20, 2021. Mag Magna Corp is engaged in organizational activities and intends to expand the company's activities for distributing, marketing, and selling formula for feed additives, using new technologies in the near future.

Mag Magna Corp has a long-term partnership agreement with Ipax LLC ("Ipax"), a Wyoming company. Under the aforementioned Patent License and Assignment Agreement ("Agreement"), Mag Magna Corp has the exclusive right to distribute, market and sell a formula of feed additives that strengthens the immunity of poultry in the U.S. market.

According to the Agreement, Ipax provides a unique chemical composition of the formula and advisory services to Mag Magna Corp that is focused on improving, promoting, boosting, enhancing, and distributing the formula for development of feed additives without antibiotics in the market. Together with Ipax, Mag Magna Corp distributes a methodology that allows raising poultry meat under industrial conditions, avoiding antibiotics at all stages of poultry breeding, both for therapeutic and prophylactic purposes. The two essential components are MAGA and CHASIS through which we can replace antibiotics with a more environmentally friendly formula. Mag Magna Corp is founded on an innovative approach, stability, confidentiality, and guarantee.

MAGA is a concentrated substance-immunostimulant for oral use. MAGA is an oily concentrate that dissolves well in water and has a characteristic smell of herbs and proves to be an essential component in poultry ration. Its properties include:

● strengthening and stimulating the body's immune system;

● ensuring energy exchange processes;

● contributing to the restoration of optimal intestinal microflora;

● eliminating inflammatory processes;

● normalization of metabolism;

● protecting from pathogenic microorganisms;

● neutralizing the toxic manifestations;

● activating enzyme reactions;

● reducing the effect of stress factors;

● bactericidal and hepatoprotective properties.

It is used to increase the assimilation of nutrients, eliminate intoxications, stimulate, and normalize metabolism, increase the body's general resistance, and normalize digestive processes.

CHASIS is a concentrate with a characteristic smell of wormwood. CHASIS is a feed additive that contains a stabilizer of intestinal microflora. This stabilizer is used to stimulate metabolic processes, prevent bacterial and viral diseases, and adapt to adverse environmental conditions. It helps to inhibit the growth of pathogenic enterobacteria and normalize intestinal microflora. Moreover, it stabilizes the digestive system, increases nonspecific resistance and metabolic processes, has a positive effect on productivity, reproduction, bird safety, normalizes intestinal passage, saves feed consumption, and improves feed digestibility.

Product quality, safety, and the emergence and re-emergence of various diseases still present a challenge to the current market situation and future industry. Among the factors directly impacting the growth of the poultry industry are poultry immunity, health, and production. Foodborne and zoonotic diseases are strictly related to poultry. Spreading pathogens can represent a potential threat to human health. Apart from that, there are health hazards related to consuming foods with high antibiotic residues, and they remain a critical issue. However, it is necessary to point out that chickens are not susceptible to intranasal infection by the SARS-CoV-2 (COVID-19) virus.

Immunity is one of the key factors in protecting animals and controlling diseases. The health of animals is mediated by immunity and the risk of infection and invading pathogens. Chickens develop their immune system during various stages of life. They also depend on different types of immunity to protect themselves, such as natural or innate immunity from limiting pathogen growth.

**Liquidity and Capital Resources**

As of April 30, 2022, the company has $4,501 in current assets. As of April 30, 2022, the company has $2,950 in liabilities and net income of $1.

As of October 31, 2022, the company has $4,506 in current assets. As of October 31, 2022, the company has $16,135 in liabilities and an accumulated deficit of $6,894.

Net cash used in operating activities for the year ended April 30, 2022, was $0.

Cash flows from financing activities for the year ended April 30, 2022 was $1

The Use of Proceeds section includes a detailed description of the use of proceeds over the differing offering scenarios of 100%, 75%, 50% and 25%. As the Company's expenses are relatively stable, unless additional sites are rolled out, the Company believes it can continue its present operations with projected revenues together with offering proceeds under any of the offering scenarios. The Company will consider raising additional funds through sales of equity, debt, and convertible securities, if it is deemed necessary. The Company has no intention in investing in short-term or long-term discretionary financial programs of any kind.

**Components of Results of Operations**

**Results of Operations**

We have not generated any revenue since inception till April 30, 2022.

Mag Magna Corp has incurred no expenses for the year ended April 30, 2022.

Total expenses for the period ended October 31, 2022, were $3,600 consisting of General and administrative expenses, $74 in Bank Service charges and $164 in Depreciation Expense.

The company recorded a net income of $1 for the year ended April 30, 2022.

The company recorded a net loss of $3,836 for the three months ended October 31, 2022.

**Operating Expenses**

 

General and Administrative

General and administrative expenses consist of personnel-related costs, including salaries, employee benefits, and stock-based compensation charges for personnel in executive, finance and other administrative functions. Other significant costs include facility-related costs, legal fees relating to intellectual property and corporate matters, professional fees for accounting and consulting services, and insurance costs. We anticipate that our general and administrative expenses will increase substantially for the foreseeable future to support our continued research and development activities, pre-commercial preparation activities for our product candidates, and, if any vaccine candidate receives marketing approval, commercialization activities. Following the completion of this offering, we also anticipate increased expenses related to audit, legal, regulatory, and tax-related services associated with maintaining compliance with exchange listing and SEC requirements, director and officer insurance premiums, and investor relations costs associated with operating as a public company.

**Critical Accounting Policies and Significant Judgments and Estimates**

Our financial statements are prepared in accordance with generally accepted accounting principles in the United States (GAAP). The preparation of our financial statements requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, costs, and expenses and the disclosure of contingent assets and liabilities in our financial statements and accompanying notes. We base our estimates and assumptions on historical experience and other factors that we believe to be reasonable under the circumstances. We evaluate our estimates and judgments on an ongoing basis. We base our estimates on historical experience, known trends and events, and on various other factors that we believe are reasonable under the circumstances, the results of

which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Our actual results may differ materially from these estimates under different assumptions or conditions.

While our significant accounting policies are more fully described in Note 3 to our audited financial statements and Note 3 to our unaudited interim condensed financial statements included elsewhere in this prospectus, we believe that the mentioned accounting policies are the most critical for fully understanding and evaluating our financial condition and results of operations according to the Note 3.

**Off-Balance Sheet Arrangements**

During the periods presented we did not have, nor do we currently have, any off-balance sheet arrangements as defined under SEC rules.

**BUSINESS**

**Overview**

Mag Magna Corp is a Wyoming company incorporated on September 20, 2021. Mag Magna Corp is engaged in organizational activities and intends to expand the company's activities for distributing, marketing, and selling formula for feed additives, using new technologies in the near future.

Mag Magna Corp has a long-term partnership agreement with Ipax LLC ("Ipax"), a Wyoming company. Under the aforementioned Patent License and Assignment Agreement ("Agreement"), Mag Magna Corp has the exclusive right to distribute, market and sell a formula of feed additives that strengthens the immunity of poultry in the U.S. market.

According to the Agreement, Ipax provides a unique chemical composition of the formula and advisory services to Mag Magna Corp that is focused on improving, promoting, boosting, enhancing and distributing the formula for development of feed additives without antibiotics in the market. Together with Ipax, Mag Magna Corp. distributes a methodology that allows raising poultry meat under industrial conditions, avoiding antibiotics at all stages of poultry breeding, both for therapeutic and prophylactic purposes. The two essential components are MAGA and CHASIS through which we can replace antibiotics with a more environmentally friendly formula. Mag Magna Corp is founded on an innovative approach, stability, confidentiality, and guarantee.

MAGA is a concentrated substance-immunostimulant for oral use. MAGA is an oily concentrate that dissolves well in water and has a characteristic smell of herbs and proves to be an essential component in poultry ration. Its properties include:

● strengthening and stimulating the body's immune system;

● ensuring energy exchange processes;

● contributing to the restoration of optimal intestinal microflora;

● eliminating inflammatory processes;

● normalization of metabolism;

● protecting from pathogenic microorganisms;

● neutralizing the toxic manifestations;

● activating enzyme reactions;

● reducing the effect of stress factors;

● bactericidal and hepatoprotective properties.

It is used to increase the assimilation of nutrients, eliminate intoxications, stimulate and normalize metabolism, increase the body's general resistance, and normalize digestive processes.

The unique formula of "MAGA" has a bactericidal effect against gram-negative and gram-positive microorganisms, eliminates inflammatory processes in the gastrointestinal tract (including the oviduct in laying hens), inhibits toxic phenomena, preventing the accumulation of toxins from feed, has a general stimulating, tonic,

adaptogen and anti-stress effect. The selected formulation, namely the composition of extracts: sprouts of wheat, wormwood, amaranth, nettle, magnesium chloride, etc., ensures normalization of metabolism in farm animals and poultry, improves the overall body resistance, regeneration of mucous membranes, increases the intensity and prolongation of egg production in laying hens, stimulates the digestive system, supplements the ovary of laying hens with macro- and microelements necessary for reproduction, increases the processes of poultry and animal weight formation, has hepatoprotective properties.

CHASIS is a concentrate with a characteristic smell of wormwood. CHASIS is a feed additive that contains a stabilizer of intestinal microflora. This stabilizer is used to stimulate metabolic processes, prevent bacterial and viral diseases, and adapt to adverse environmental conditions. It helps to inhibit the growth of pathogenic enterobacteria and normalize intestinal microflora. Moreover, it stabilizes the digestive system, increases nonspecific resistance and metabolic processes, has a positive effect on productivity, reproduction, bird safety, normalizes intestinal passage, saves feed consumption, and improves feed digestibility.

The "CHASIS" feed additive is an active substance consisting of alkaloids obtained by the extraction of medicinal plants, which is a source of natural phyto components that are absorbed by 95-98%. Unique properties of the formulation improve performance in monogastric animals and poultry.

It normalizes the functioning of the gastrointestinal tract and microflora. It restores the optimal pH value in the gastrointestinal tract, increases body resistance to infections and toxin buildup, has anti-inflammatory,antiseptic and hepatoprotective properties. It has an antimicrobial and virucidal effect, eliminates feed losses and improves its digestibility, and increases absorption of amino acids. It reduces oviduct inflammation (for laying hens), has an anthelmintic effect. It prevents oxidation of fats, fatty acids and sterols that may contribute to toxicosis. It improves general health of poultry, enhances feed conversion, egg production. The "CHASIS" feed additive contains no genetically modified substances.

The additive is used throughout the entire rearing period. It increases the efficiency of feeding and absorption of feed. It is used in the period of stress and prevention of infectious diseases, to optimize the absorption of nutrients, improves the adsorption of amino acids and reduces the number of mediators of inflammatory processes.

Product quality, safety, and the emergence and re-emergence of various diseases still present a challenge to the current market situation and future industry. Among the factors directly impacting the growth of the poultry industry are poultry immunity, health, and production. Foodborne and zoonotic diseases are strictly related to poultry. Spreading pathogens can represent a potential threat to human health. Apart from that, there are health hazards related to consuming foods with high antibiotic residues, and they remain a critical issue. However, it is necessary to point out that chickens are not susceptible to intranasal infection by the SARS-CoV-2 (COVID-19)

virus.

Immunity is one of the key factors in protecting animals and controlling diseases. The health of animals is mediated by immunity and the risk of infection and invading pathogens. Chickens develop their immune system during various stages of life. They also depend on different types of immunity to protect themselves, such as natural or innate immunity from limiting pathogen growth.

Ipax registered both formulas 'CHASIS' and 'MAGA' in Eastern Europe. Please see Registration Certificates and Appendix to Registration certificates of MAGA and CHASIS filed as Exhibits 99.2-99.5.

**Our Industry**

The U.S. poultry industry is a large, attractive, and growing sector, driven by strong demand for and consumption of chicken in the United States. It also has a potential for growing export markets around the world.

The United States has a robust poultry industry, which makes up a significant part of the country's agricultural economy. U.S. poultry farming is a large and growing sector, supported by competitive production structures, a variety of methods in poultry breeding, abundant domestic feed resources, and strong consumer appeal.

According to Poultry Global Market Report 2022, the global poultry market size is expected to grow to $493.21 billion in 2026 at a CAGR of 8.9%. Given the dynamics in the development of the poultry market, meat consumption in the U.S. is on the rise. The demand for chicken in the U.S. is linked to reduced consumption of beef and pork.

The U.S. Department of Agriculture ("USDA") claims U.S. poultry production has a competitive advantage in the world due to abundant domestic feed resources, mainly soybean meal and corn. Poultry feeding is the key to quality and healthy human food products such as meat and eggs. Modern poultry genetics drove a dramatic increase in poultry farming, requiring less feed and time to produce chickens ready for consumption and resulting in highly competitive product prices.

**Our Growth Strategy**

Our growth strategy is focused on these major areas:

Expansion And Optimization

Mag Magna Corp plans to establish and grow future partner relationships with companies, ready and willing to introduce alternatives to antibiotic feed additives. The initial focus is on optimizing existing properties of components and incrementally expanding the Company's capabilities. We have explored opportunities and increased demand for alternative feed additives that can be used to improve animal production, allowing us to take advantage of capacity expansion opportunities. Mr. Oleg Bilinski, our sole officer, and director, continually works to identify production bottlenecks and develop plans to eliminate them. Furthermore, the Company aims at capitalizing on prosperous export market trends for U.S. poultry feed.

Continued Product Innovation

 

The Company aims to coordinate with the partners to continually develop processes that meet their needs, including the opportunity to expand the depth and breadth of our further product offerings. The Agreement provides for the development, distribution, marketing, and sale of the feed additives formula. The Company is to operate in each of these directions, seeking strategic partners engaged in the development and manufacture of chemical compounds for feed additives becoming a prime focus. Providing a chemical formula, we foster further development and market entry of antibiotic-free products.

**Competition**

The poultry industry is highly competitive, and some of our competitors have greater financial and marketing resources than we do. In the United States, we compete with other vertically integrated poultry companies engaged in production of feed additives.

In general, the competitive factors in the U.S. poultry industry include price, product quality, product development, brand identification, breadth of product line and customer service. Competitive factors vary by major market. In the feed additives market, we believe that competition is based on consistent quality, product development, service and price. In the U.S. retail market, we believe that product quality, brand awareness and customer service are the primary bases of competition.

**Material Agreements** 

*Patent License and Assignment Agreement* 

On November 15, 2022, Mag Magna Corp. entered into a Patent License and Assignment Agreement (Agreement) with Ipax LLC. Pursuant to the Agreement, Mag Magna Corp. received an exclusive right to distribute, market, and sell any product covered by the licensed patents, or licensed products assigned by Ipax. The Agreement was entered into on an exclusive basis.

The Agreement will remain in effect during the five years commencing on the date the Agreement was entered (Effective Date). Under the Agreement, Mag Magna Corp. is required to pay Ipax LLC a royalty of twenty percent of product sale manufactured, sold, or imported in the territory of North America. All royalty payments to Ipax LLC will be made at the end of the reporting period of the Company. Ipax LLC agreed to provide a chemical formula for additive development and advisory services to the Company. Mag Magna Corp obtained copies of registration certificates for CHASIS and MAGA components from Ipax LLC and Ipax LLC granted an exclusive right to the Company.

**Government Regulation and further Product Approval**

The FDA and other regulatory authorities at federal, state, and local levels, as well as in foreign countries, extensively regulate, among other things, the research, development, testing, manufacture, quality control, import, export, safety, effectiveness, labeling, packaging, storage, distribution, record keeping, approval, advertising, promotion, marketing, post-approval monitoring, and post-approval reporting of biologics such as those we are developing. We, along with third-party contractors, will be required to navigate the various preclinical, clinical, and commercial approval requirements of the governing regulatory agencies of the countries in which we wish to conduct studies or seek approval or licensure of our product candidates. The process of obtaining regulatory approvals and the subsequent compliance with applicable federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources. As formula developed by Ipax LLC is designed as a feed additive, it is a subject of regulation by FDA in the section "Animal & Veterinary" as animal food & feeds. The Company plans to submit the application to the FDA in the future to demonstrate to the future customers that the additive is safe for the proposed use in animal food in the event of its preparation for distribution. Moreover, receiving this approval will affect further consumer confidence in us.

**Legal Proceedings**

From time to time, we may become involved in legal proceedings or be subject to claims arising in the ordinary course of our business. We are not currently a party to any material proceedings. Regardless of outcome, such proceedings or claims can have an adverse impact on us because of defense and settlement costs, diversion of resources and other factors, and there can be no assurances that favorable outcomes will be obtained.

**Employees**

We have 1 (one) employee as of the date of this prospectus – Oleg Bilinski, our sole officer and director. Oleg Bilinski, currently devotes as much time as needed to provide management services to company matters. After receiving funding, Mr. Bilinski plans to devote as much time to the operation of the Company as he determines is necessary for him to manage the affairs of the Company. As our business and operations increase, we will assess the need for full-time management and administrative support personnel.

**Offices**

Our business office is located at 325 W Washington St Ste 2877 San Diego, CA 92103*.* There is no formal rent agreement. Our telephone number is +16204692043*.*

**MANAGEMENT**

**Executive Officers and Directors**

The name, age and titles of our executive officer and director are as follows:

---

| | | | |
|:---|:---|:---|:---|
| **NAME** | **AGE** | **AGE** | **POSITION** |
| ***Executive Officers*** |  |  |  |
| Oleg Bilinski |  | 62 | President, Chief Executive Officer, Secretary, Treasurer and Director |

---

Oleg Bilinski has served as our President, Chief Executive Officer, Secretary, Treasurer and Director and on our board of directors since our inception on September 20, 2021. Mr. Bilinski owns 100% of the outstanding shares of our common stock.

Since 2010, Mr. Bilinski has been involved in commercial and residential real estate investments in Europe and North America. In 2008 Mr. Bilinski became President and CEO of Mass Petroleum Inc. Since 1990, Mr. Bilinski has served as the President of the UK International Trade Corporation, focusing on establishing business relationships between North America and Eastern Europe. Mr. Bilinski has considerable investing experience in start-ups and public companies.

Mr. Bilinski holds an MSc degree in Specialty Microbiology and Chemistry from the National University of Lviv. Mr. Bilinski has an extensive knowledge base and will be able to expand the company's staff and collaborate with highly competent specialists in the pharmaceutical industry.

During the past ten years our President, Chief Executive Officer, Secretary, Treasurer and Director, Mr. Bilinski has not been the subject to any of the following events:

* Any bankruptcy petition filed by or against any business of which Mr.
Bilinski was a general partner or executive officer either at the time of the bankruptcy or within two years prior to that time.

* Any conviction in a criminal proceeding or being subject to a pending criminal
proceeding.

* An order, judgment, or decree, not subsequently reversed, suspended or vacated,
or any court of competent jurisdiction, permanently or temporarily enjoining, barring, suspending or otherwise limiting Mr. Bilinski's
involvement in any type of business, securities or banking activities.

* Found by a court of competent jurisdiction (in a civil action), the Securities
and Exchange Commission or the Commodity Future Trading Commission to have violated a federal or state securities or commodities law,
and the judgment has not been reversed, suspended or vacated.

* Was the subject of any order, judgment or decree, not subsequently reversed,
suspended or vacated, of any Federal or State authority barring, suspending or otherwise limiting for more than 60 days the right to engage
in any activity described in paragraph (f)(3)(i) of this section, or to be associated with persons engaged in any such activity;

* Was found by a court of competent jurisdiction in a civil action or by the
Commission to have violated any Federal or State securities law, and the judgment in such civil action or finding by the Commission has
not been subsequently reversed, suspended, or vacated;

* Was the subject of, or a party to, any Federal or State judicial or administrative
order, judgment, decree, or finding, not subsequently reversed, suspended or vacated, relating to an alleged violation of:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;i. Any Federal or State securities or commodities law or regulation; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ii. Any law or regulation respecting financial institutions or insurance companies including, but not limited to, a temporary or permanent injunction, order of disgorgement or restitution, civil money penalty or temporary or permanent cease-and-desist order, or removal or prohibition order; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;iii. Any law or regulation prohibiting mail or wire fraud or fraud in connection with any business entity;

**Term Of Office**

Our Director is appointed to hold office until the next annual meeting of our stockholders or until his respective successor is elected and qualified, or until he resigns or is removed in accordance with the provisions of the Wyoming Revised Statutes. Our officers are appointed by our Board of Directors and hold office until removed by the Board or until their resignation.

**Director Independence**

Our Board of Directors is currently composed of one member, Oleg Bilinski, who does not qualify as an independent director. Our board of directors has not made a subjective determination as to each director that no relationships exist which, in the opinion of our board of directors, would interfere with the exercise of independent judgment in carrying out the responsibilities of a director Had our Board of Directors made these determinations, our board of directors would have reviewed and discussed information provided by the directors and us with regard to each director's business and personal activities and relationships as they may relate to us and our management.

**Committees Of The Board Of Directors**

Our Board of Directors has no committees. We do not have a standing nominating, compensation, or audit committee.

**EXECUTIVE COMPENSATION** 

Our current director does not receive compensation for his service on our Board of Directors. Our Board has the authority to fix the compensation of directors.

The following tables set forth certain information about compensation paid, earned or accrued for services by our Executive Officer from inception on September 20, 2021, until October 31, 2022:

**Summary Compensation Table** 

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| &nbsp;&nbsp;Name and Principal Position | &nbsp;&nbsp;Period | &nbsp;&nbsp;Salary ($) | &nbsp;&nbsp;Bonus ($) | &nbsp;&nbsp;Stock Awards ($) | &nbsp;&nbsp;Option Awards ($) | &nbsp;&nbsp;Non-Equity Incentive Plan Compensation ($) | &nbsp;&nbsp;All Other Compensation ($) | &nbsp;&nbsp;Total ($) |
| &nbsp;&nbsp;Oleg Bilinski, President, Treasurer, Secretary and Director | &nbsp;&nbsp;September 20, 2021 until October 31, 2022 | &nbsp;&nbsp;-0- | &nbsp;&nbsp;-0- | &nbsp;&nbsp;-0- | &nbsp;&nbsp;-0- | &nbsp;&nbsp;-0- | &nbsp;&nbsp;-0- | &nbsp;&nbsp;-0- |

---

There are no current employment agreements between the Company and the Director.

**CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS**

Other than Mr. Bilinski purchase of founders shares from the Company as stated below, there is nothing of value (including money, property, contracts, options or rights of any kind), received or to be received, by Mr. Bilinski, directly or indirectly, from the Company.

On November 26, 2021, we issued a total of 4,500,000 shares of Common stock to Oleg Bilinski, our president, treasurer, secretary and director in consideration of $4,500.

Further, effective December 2, 2021, Mr. Bilinski formally agreed to advance funds to the Company to loan the Company the principal sum of $60,000 for business development under a Loan Agreement. The Loan Agreement is non-binding and discretionary, bears no interest, is unsecured, and is due and payable on or before December 2, 2028.

There are no promoters of the company, and have been none, as defined in Item 404(c)(1)(i) of Regulation S-K, other than Mag Magna director Oleg Bilinski.

**PRINCIPAL STOCKHOLDERS**

The following table sets forth, as of the date of this prospectus, the total number of shares owned beneficially by our directors, officers and key employees, individually and as a group, and the present owners of 5% or more of

our total outstanding shares. The table also reflects what their ownership will be assuming completion of the sale of all shares in this offering. The stockholders listed below have direct ownership of their shares and possess sole voting and dispositive power with respect to the shares.

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Name and Address**<br> **Beneficial Owner [1]** | **Number of Shares Before the Offering** | **Percentage of Ownership Before the Offering** | **Number of Shares After Offering Assuming all of** t**he Shares are Sold** | **Percentage of Ownership After the Offering Assuming all of the Shares are Sold** |
| Oleg Bilinski | 4500000 | 100% | 4500000 | 52.94% |

---

[1] The person named above may be deemed to be a" parent*"* and" promoter*"* of our company, within the meaning of such terms under the Securities Act of 1933, as amended, by virtue of his direct and indirect stock holdings. Mr. Bilinski is the only" promoter*"* of our company.

**Future sales by existing stockholders**

A total of 4,500,000 shares of common stock were issued to our president, treasurer, secretary, and director, all of which are restricted securities, as defined in Rule 144 of the Rules and Regulations of the SEC promulgated under the Securities Act. Under Rule 144, the shares can be publicly sold, subject to volume restrictions and restrictions on the manner of sale. Such shares can only be sold after six months provided that the issuer of the securities is and has been for a period of at least 90 days immediately before the sale, subject to the reporting requirements of section 13 or 15(d) of the Exchange Act. Shares purchased in this offering, which will be immediately resalable, and sales of all of our other shares after applicable restrictions expire, could have a depressive effect on the market price, if any, of our common stock and the shares we are offering.

There is no public trading market for our common stock. To be quoted on the OTCQB a market maker must file an application on our behalf to make a market for our common stock. As of the date of this Registration Statement, we have not engaged a market maker to file such an application, that there is no guarantee that a market marker will file an application on our behalf, and that even if an application is filed, there is no guarantee that we will be accepted for quotation.

**PLAN OF DISTRIBUTION**

We are registering 4,000,000 shares of our common stock for sale at the price of $0.025 per share.

This is a self-underwritten offering, and Mr. Bilinski, our president, treasurer, secretary and director, will sell the shares directly to family, friends, business associates and acquaintances, with no commission or other remuneration payable to his for any shares they may sell. There are no plans or arrangements to enter into any contracts or agreements to sell the shares with a broker or dealer. In offering the securities on our behalf, he will rely on the safe harbor from broker dealer registration set out in Rule 3a4-1 under the Securities Exchange Act of 1934. Mr. Bilinski will not register as a broker-dealer pursuant to Section 15 of the Securities Exchange Act of 1934, in reliance upon Rule 3a4-1, which sets forth those conditions, as noted herein, under which a person associated with an Issuer may participate in the offering of the Issuer's securities and not be deemed to be a broker-dealer:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. Our president, treasurer, secretary and director is not subject to a statutory disqualification, as that term is defined in Section 3(a)(39) of the Act, at the time of his participation; and,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. Our president, treasurer, secretary and director will not be compensated in connection with his participation by the payment of commissions or other remuneration based either directly or indirectly on transactions in securities; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. Our president, treasurer, secretary and director is not, nor will he be at the time of his participation in the offering, an associated person of a broker-dealer; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. Our president, treasurer, secretary and director meets the conditions of paragraph (a)(4)(ii) of Rule 3a4-1 of the Exchange Act, in that he (A) primarily perform, or intend primarily to perform at the end of the offering, substantial duties for or on behalf of our Company, other than in connection with transactions in securities; and (B) he is not a broker or dealer, or been an associated person of a broker or dealer, within the preceding twelve months; and (C) has not participated in selling and offering securities for any issuer more than once every twelve months other than in reliance on Paragraphs (a)(4)(i) or (a)(4)(iii). Under Paragraph 3a4-1(a)(4)(iii), our president, treasurer, secretary and director must restrict his participation to any one or more of the following activities:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. Preparing any written communication or delivering such communication through the mails or other means that does not involve oral solicitation by his of a potential purchaser; provided, however, that the content of such communication is approved by our president, treasurer, secretary and director.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b. Responding to inquiries of a potential purchaser in a communication initiated by the potential purchaser; provided, however, that the content of such responses are limited to information contained in a registration statement filed under the Securities Act of 1933 or other offering document; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c. Performing ministerial and clerical work involved in effecting any transaction.

Our president, treasurer, secretary, and director does not intend to purchase any shares in this offering.

This offering is self-underwritten, which means that it does not involve the participation of an underwriter or broker, and as a result, no broker for the sale of our securities will be used. In the event a broker-dealer is retained by us to participate in the offering, we must file a post-effective amendment to the registration statement to disclose the arrangements with the broker-dealer, and that the broker-dealer will be acting as an underwriter and will be so named in the prospectus. Additionally, FINRA must approve the terms of the underwriting compensation before the broker-dealer may participate in the offering.

To the extent required under the Securities Act, a post-effective amendment to this registration statement will be filed disclosing the name of any broker-dealers, the number of shares of common stock involved, the price at which the common stock is to be sold, the commissions paid or discounts or concessions allowed to such broker-dealers, where applicable, that such broker-dealers did not conduct any investigation to verify the information set out or incorporated by reference in this prospectus and other facts material to the transaction.

We are subject to applicable provisions of the Exchange Act and the rules and regulations under it, including, without limitation, Rule 10b-5 and a distribution participant under Regulation M. All of the foregoing may affect the marketability of the common stock.

All expenses of the registration statement including, but not limited to, legal, accounting, printing and mailing fees are and will be borne by us.

**Penny Stock Regulations**

You should note that our stock is a penny stock. The SEC has adopted Rule 15g-9 which generally defines "penny stock" to be any equity security that has a market price (as defined) less than $5.00 per share or an exercise price of less than $5.00 per share, subject to certain exceptions. Our securities are covered by the penny stock rules, which impose additional sales practice requirements on broker-dealers who sell to persons other than established customers and "accredited investors". The term "accredited investor" refers generally to institutions with assets in excess of $5,000,000 or individuals with a net worth in excess of $1,000,000 or annual income exceeding $200,000 or $300,000 jointly with their spouse. The penny stock rules require a broker-dealer, prior to a transaction in a penny stock not otherwise exempt from the rules, to deliver a standardized risk disclosure document in a form prepared by the SEC which provides information about penny stocks and the nature and level of risks in the penny stock market. The broker-dealer also must provide the customer with current bid and offer quotations for the penny stock, the compensation of the broker-dealer and its salesperson in the transaction and monthly account statements showing the market value of each penny stock held in the customer's account. The bid and offer quotations, and the broker-dealer and salesperson compensation information, must be given to the customer orally or in writing prior to effecting the transaction and must be given to the customer in writing before or with the customer's confirmation. In addition, the penny stock rules require that prior to a transaction in a penny stock not otherwise exempt from these rules, the broker-dealer must make a special written determination that the penny stock is a suitable investment for the purchaser and receive the purchaser's written agreement to the transaction. These disclosure requirements may have the effect of reducing the level of trading activity in the secondary market for the stock that is subject to these penny stock rules. Consequently, these penny stock rules may affect the ability of broker-dealers to trade our securities. We believe that the penny stock rules discourage investor interest in and limit the marketability of our common stock.

**Procedures for Subscribing**

If you decide to subscribe for any shares in this offering, you must

▪ execute and deliver a subscription agreement; and

▪ deliver a check or certified funds to us for acceptance or rejection.

All checks for subscriptions must be made payable to Mag Magna Corp. The Company will deliver stock certificates attributable to shares of common stock purchased directly to the purchasers.

**Right to Reject Subscriptions**

We have the right to accept or reject subscriptions in whole or in part, for any reason or for no reason. All monies from rejected subscriptions will be returned immediately by us to the subscriber, without interest or deductions. Subscriptions for securities will be accepted or rejected with letter by mail within 48 hours after we receive them.

**DESCRIPTION OF SECURITIES**

The following description as a summary of the material terms of the provisions of our Articles of Incorporation and Bylaws. The Articles of Incorporation and Bylaws have been filed as exhibits to the registration statement of which this prospectus is a part.

**Common Stock**

Our authorized capital stock consists of 75,000,000 shares of common stock, par value $0.0010 per share. As of October 31, 2021, there were 4,500,000 shares of our common stock issued and outstanding those were held by one registered stockholder of record and no shares of preferred stock issued and outstanding. Our president, treasurer, secretary and director, Oleg Bilinski owns all 4,500,000 shares of our common stock currently issued and outstanding.

**Preferred Stock** 

We do not have an authorized class of preferred stock.

**Warrants** 

We have not issued and do not have any outstanding warrants to purchase shares of our common stock.

**Options** 

We have not issued and do not have any outstanding options to purchase shares of our common stock.

**Convertible Securities** 

We have not issued and do not have any outstanding securities convertible into shares of our common stock or any rights convertible or exchangeable into shares of our common stock.

**Dividend Policy**

We have never declared or paid any cash dividends on our common stock. We currently intend to retain future earnings, if any, to finance the expansion of our business. As a result, we do not anticipate paying any cash dividends in the foreseeable future.

**Limitations of Liability and Indemnification Matters**

For a discussion of liability and indemnification, see "Executive and Director Compensation—Limitations of Liability and Indemnification Matters."

**Material United States Federal Income Tax Consequences to Non-U.S. Holders**

The following discussion is a summary of the material U.S. federal income tax consequences to non-U.S. Holders (as defined below) of the purchase, ownership and disposition of our common stock issued pursuant to this offering but does not purport to be a complete analysis of all potential tax effects. The effects of other U.S. federal tax laws, such as estate and gift tax laws, and any applicable state, local or non-U.S. tax laws are not discussed. This discussion is based on the U.S. Internal Revenue Code of 1986, as amended (the Code) Treasury Regulations promulgated thereunder, judicial decisions, and published rulings and administrative pronouncements of the U.S. Internal Revenue Service (the IRS) in each case in effect as of the date hereof. These authorities may change or be subject to differing interpretations. Any such change or differing interpretation may be applied retroactively in a manner that could adversely affect a non-U.S. Holder of our common stock. We have not sought and will not seek any rulings from the IRS regarding the matters discussed below. There can be no assurance the IRS or a court will not take a contrary position to that discussed below regarding the tax consequences of the purchase, ownership and disposition of our common stock.

This discussion is limited to non-U.S. Holders that hold our common stock as a "capital asset" within the meaning of Section 1221 of the Code (generally, property held for investment). This discussion does not address all U.S. federal income tax consequences relevant to a Non-U.S. Holder's particular circumstance, including the impact of the alternative minimum tax or the Medicare contribution tax on net investment income. In addition, it does not address consequences relevant to non-U.S. Holders subject to special rules, including, without limitation:

- U.S. expatriates and former citizens or long-term residents of the United States;

- persons holding our common stock as part of a hedge, straddle or other risk reduction strategy or as part of a conversion transaction or other integrated investment;

- banks, insurance companies, and other financial institutions;

- brokers, dealers or traders in securities;

- "controlled foreign corporations," "passive foreign investment companies," and corporations that accumulate earnings to avoid U.S. federal income tax;

- partnerships or other entities or arrangements treated as partnerships for U.S. federal income tax purposes (and investors therein);

- tax-exempt organizations or governmental organizations;

- persons deemed to sell our common stock under the constructive sale provisions of the Code;

- persons who hold or receive our common stock pursuant to the exercise of any employee stock option or otherwise as compensation;

- persons subject to special tax accounting rules as a result of any item of gross income with respect to our common stock being taken into account in an "applicable financial statement" (as defined in the Code);

- tax-qualified retirement plans; and

- "qualified foreign pension funds" as defined in Section 897(l)(2) of the Code and entities all of the interests of which are held by qualified foreign pension funds.

If an entity treated as a partnership for U.S. federal income tax purposes holds our common stock, the tax treatment of a partner in the partnership will depend on the status of the partner, the activities of the partnership and certain determinations made at the partner level. Accordingly, partnerships holding our common stock and the partners in such partnerships should consult their tax advisors regarding the U.S. federal income tax consequences to them.

**THIS DISCUSSION IS FOR INFORMATION PURPOSES ONLY AND IS NOT TAX ADVICE. INVESTORS SHOULD CONSULT THEIR TAX ADVISORS WITH RESPECT TO THE APPLICATION OF THE U.S. FEDERAL INCOME TAX LAWS TO THEIR PARTICULAR SITUATIONS AS WELL AS ANY TAX CONSEQUENCES OF THE PURCHASE, OWNERSHIP AND DISPOSITION OF OUR COMMON STOCK ARISING UNDER THE U.S. FEDERAL ESTATE OR GIFT TAX LAWS OR UNDER THE LAWS OF ANY STATE, LOCAL OR NON-U.S. TAXING JURISDICTION OR UNDER ANY APPLICABLE INCOME TAX TREATY.**

**Definition of a Non-U.S. Holder**

For purposes of this discussion, a "non-U.S. Holder" is any beneficial owner of our common stock that is neither a "U.S. person" nor an entity treated as a partnership for U.S. federal income tax purposes. A U.S. person is any person that, for U.S. federal income tax purposes, is or is treated as any of the following:

- an individual who is a citizen or resident of the United States;

- a corporation created or organized under the laws of the United States, any state thereof;

- an estate, the income of which is subject to U.S. federal income tax regardless of its source; or

- a trust that (i) is subject to the primary supervision of a U.S. court and the control of one or more "United States persons" (within the meaning of Section 7701(a)(30) of the Code), or (ii) has a valid election in effect to be treated as a United States person for U.S. federal income tax purposes.

**LEGAL MATTERS**

The validity of the shares of common stock offered hereby will be passed upon for us by LinnLaw Corporation, address: 1100 Melody Lane, Suite 2001, Roseville, CA 95678.

**EXPERTS**

Ben, BF Borgers CPA PC, independent registered public accounting firm, has audited our financial statements as of April 30, 2022, as set forth in their report. Ben, BF Borgers CPA PC has presented its report with respect to our audited financial statements. Such financial statements are included in this prospectus in reliance upon the report of such firm given upon their authority as experts in accounting and auditing.

**WHERE YOU CAN FIND MORE INFORMATION**

We have filed with the SEC a registration statement on Form S-1 under the Securities Act with respect to the shares of common stock offered hereby. This prospectus, which constitutes a part of the registration statement, does not contain all of the information set forth in the registration statement or the exhibits and schedules filed therewith. For further information about us and the common stock offered hereby, we refer you to the registration statement and the exhibits and schedules filed thereto. Statements contained in this prospectus regarding the contents of any contract or any other document that is filed as an exhibit to the registration statement are not necessarily complete, and each such statement is qualified in all respects by reference to the full text of such contract or other document filed as an exhibit to the registration statement. Upon the closing of this offering, we will be required to file periodic reports, proxy statements and other information with the SEC pursuant to the Exchange Act. The SEC maintains an Internet website that contains reports, proxy statements and other information about registrants, like us, that file electronically with the SEC. The address of that site is www.sec.gov.

Upon the closing of this offering, we will become subject to the information and periodic reporting requirements of the Exchange Act and, in accordance therewith, will file periodic reports, proxy statements and other information with the SEC. Such periodic reports, proxy statements and other information will be available at the website of the SEC referred to above. We maintain a website at <u>https://magmagna.com</u>. Upon the closing of this offering, you may access our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act with the SEC free of charge at our website as soon as reasonably practicable after such material is electronically filed with, or furnished to, the SEC. The reference to our website address does not constitute incorporation by reference of the information contained on our website, and you should not consider the contents of our website in making an investment decision with respect to our common stock.

**MAG MAGNA CORP**

**FINANCIAL STATEMENTS**

Our fiscal year end is April 30. We will provide audited financial statements to our stockholders on an annual basis; the statements will be prepared by us and audited by Ben, BF Borgers CPA PC. Our financial statements for the period ended April 30, 2022 and October 31, 2022 immediately follow.

**Mag Magna Corp**

**FINANCIAL STATEMENTS**

**As of April 30, 2022**

**INDEX TO AUDITED FINANCIAL STATEMENTS**

---

| | |
|:---|:---|
| *Report of Independent Registered Public Accounting Firm* | *F-1* |
| *Balance Sheets as of April 30, 2022* (audited) | *F-2* |
| *Statement of Operations for the period ended April 30, 2022* (audited) | *F-3* |
| *Statement of Changes in Stockholder's Equity from September 20, 2021 (Inception) to April 30, 2022* (audited) | *F-4* |
| *Statement of Cash Flows for the period ended April 30, 2022* (audited) | *F-5* |
| *Notes to the Financial Statements* | *F-6* |

---

**REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

To the shareholders and the board of directors of Mag Magna Corp

**Opinion on the Financial Statements**

We have audited the accompanying balance sheet of Mag Magna Corp (the "Company") as of April 30, 2022, the related statement of operations, stockholders' equity (deficit), and cash flows for the period September 20, 2021 (Inception) through April 30, 2022 and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of April 30, 2022, and the results of its operations and its cash flows for the period September 20, 2021 (Inception) through April 30, 2022, in conformity with accounting principles generally accepted in the United States.

**Substantial Doubt about the Company's Ability to Continue as a Going Concern**

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the financial statements, the Company's significant operating losses raise substantial doubt about its ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

**Basis for Opinion**

These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.

Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.

/S BF Borgers CPA PC

**BF Borgers CPA PC (PCAOB ID 5041)**

We have served as the Company's auditor since 2022

Lakewood, CO

November 25, 2022

MAG MAGNA CORP

BALANCE SHEET

---

| | | |
|:---|:---|:---|
|  |  | &nbsp;&nbsp; April 30, 2022<br> (audited) |
| &nbsp;&nbsp;ASSETS |  |  |
| &nbsp;&nbsp;Current Assets | &nbsp;&nbsp;Current Assets |  |
| &nbsp;&nbsp;Checking/Savings | &nbsp;&nbsp;Checking/Savings |  |
| &nbsp;&nbsp;Сash and Cash Equivalents | &nbsp;&nbsp;Сash and Cash Equivalents | &nbsp;&nbsp;4501 |
| &nbsp;&nbsp;Total Checking/Savings | &nbsp;&nbsp;Total Checking/Savings | &nbsp;&nbsp;4501 |
| &nbsp;&nbsp;Total Current Assets | &nbsp;&nbsp;Total Current Assets | &nbsp;&nbsp;4501 |
| &nbsp;&nbsp;Other Assets | &nbsp;&nbsp;Other Assets |  |
| &nbsp;&nbsp;Intangible Assets | &nbsp;&nbsp;Intangible Assets | &nbsp;&nbsp;2950 |
| &nbsp;&nbsp;Total Other Assets | &nbsp;&nbsp;Total Other Assets | &nbsp;&nbsp;2950 |
| &nbsp;&nbsp;TOTAL ASSETS | &nbsp;&nbsp;TOTAL ASSETS | &nbsp;&nbsp;7451 |
| &nbsp;&nbsp;LIABILITIES & EQUITY | &nbsp;&nbsp;LIABILITIES & EQUITY |  |
| &nbsp;&nbsp;Liabilities | &nbsp;&nbsp;Liabilities |  |
| &nbsp;&nbsp;Current Liabilities | &nbsp;&nbsp;Current Liabilities |  |
| &nbsp;&nbsp;Accounts Payable | &nbsp;&nbsp;Accounts Payable |  |
|  | &nbsp;&nbsp;Accounts Payable | &nbsp;&nbsp;2950 |
| &nbsp;&nbsp;Total Accounts Payable | &nbsp;&nbsp;Total Accounts Payable | &nbsp;&nbsp;2950 |
| &nbsp;&nbsp;Other Current Liabilities | &nbsp;&nbsp;Other Current Liabilities |  |
| Loan from Related Parties | Loan from Related Parties | &nbsp;&nbsp;- |
| &nbsp;&nbsp;Total Other Current Liabilities | &nbsp;&nbsp;Total Other Current Liabilities |  |
| &nbsp;&nbsp;Total Current Liabilities | &nbsp;&nbsp;Total Current Liabilities | &nbsp;&nbsp;2950 |
| &nbsp;&nbsp;Total Liabilities | &nbsp;&nbsp;Total Liabilities | &nbsp;&nbsp;2950 |
| &nbsp;&nbsp;Equity |  |  |
| &nbsp;&nbsp;Capital Stock | &nbsp;&nbsp;Capital Stock | &nbsp;&nbsp;4500 |
| &nbsp;&nbsp;Retained Earnings | &nbsp;&nbsp;Retained Earnings | &nbsp;&nbsp;0 |
| &nbsp;&nbsp;Net Income | &nbsp;&nbsp;Net Income | &nbsp;&nbsp;1 |
| &nbsp;&nbsp;Total Stockholders' deficit | &nbsp;&nbsp;Total Stockholders' deficit | &nbsp;&nbsp;4501 |
| &nbsp;&nbsp;TOTAL LIABILITIES & STOCKHOLDER`S DEFICIT | &nbsp;&nbsp;TOTAL LIABILITIES & STOCKHOLDER`S DEFICIT | &nbsp;&nbsp;7451 |

---

The accompanying notes are an integral part of these financial statements.

MAG MAGNA CORP

STATEMENT OF OPERATIONS

---

| | |
|:---|:---|
|  | September 20, 2021 (Inception date) -<br> April 30, 2022<br> (audited) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Revenues | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- |
| Total Revenues |  |
| Operating Expenses |  |
| General and administrative expenses | - |
| Bank service charges | - |
| Total operating expenses | - |
| Net loss from operations | - |
| Other Income | 1 |
| Provision for income taxes | - |
| <br> Net Income/Loss  | <br> 1 |
| Loss per common share – Basic & Diluted | - |
| Weighted Average Number of Common Shares Outstanding-Basic & Diluted | 4500000 |

---

The accompanying notes are an integral part of these financial statements.

MAG MAGNA CORP

STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT)

FOR THE PERIOD FROM SEPTEMBER 20, 2021 TO APRIL 30, 2022

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | Number of<br> common | Number of<br> common | Additional<br> Paid-in-<br> Capital | Accumulated<br> deficit<br>| <br>Total |
| | Shares | Amount |  |  |  |
| Balance as of September 20, 2021 | - | $- | $- | $- | $- |
| Common shares issued for cash at $0.001 | 4500000 | 4500 |  |  | 4500 |
| Net Income for the period September 20, 2021 - April 30, 2022 | - | - | - | 1 | 1 |
| Balance as of April 30, 2022 | 4500000 | $4500 | $- | $1 | $4501 |

---

The accompanying notes are an integral part of these condensed unaudited financial statements.

MAG MAGNA CORP

STATEMENTS OF CASH FLOWS

---

| | |
|:---|:---|
|  | &nbsp;&nbsp; September 20, 2021 (Inception date) -<br> April 30, 2022<br> (audited) |
| &nbsp;&nbsp;**OPERATING ACTIVITIES** |  |
| &nbsp;&nbsp;Net Income | $&nbsp;&nbsp;- |
| &nbsp;&nbsp;Adjustments to reconcile Net Income <br> to net cash provided by operations: |  |
| &nbsp;&nbsp;Prepaid Expense | &nbsp;&nbsp;0 |
| &nbsp;&nbsp;Cash Flows from Operating Activities | &nbsp;&nbsp;- |
| &nbsp;&nbsp;**FINANCING ACTIVITIES** |  |
| &nbsp;&nbsp;Capital Stock | $&nbsp;&nbsp;4500 |
| &nbsp;&nbsp;Director's Loan | &nbsp;&nbsp;- |
| &nbsp;&nbsp;Cash Flows from Financing Activities | &nbsp;&nbsp;- |
| &nbsp;&nbsp;Net cash increase for period | &nbsp;&nbsp;1 |
| &nbsp;&nbsp;Cash at beginning of period | &nbsp;&nbsp;0 |
| &nbsp;&nbsp;Cash at end of period | $&nbsp;&nbsp;4501 |

---

The accompanying notes are an integral part of these condensed unaudited financial statements.

MAG MAGNA CORP

NOTES TO THE FINANCIAL STATEMENTS

NOTE 1 – ORGANIZATION AND DESCRIPTION OF BUSINESS

MAG MAGNA CORP ("the Company") was incorporated under the laws of the State of Wyoming, U.S. on September 20, 2021 (Inception). We are engaged in organizational activities and intend to expand company`s activities for distributing, marketing, and selling formula for feed additives development, using new technologies and elaborations in the near future.

NOTE 2 - GOING CONCERN

The financial statements have been prepared on a going concern basis which assumes the Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future.

MAG MAGNA CORP has incurred no loss since Inception (September 20, 2021) and further losses are anticipated in the development of its business. Accordingly, there is substantial doubt about the Company's ability to continue as a going concern.

The ability to continue as a going concern is dependent upon the Company generating profitable operations in the future and/or to obtain the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they come due. Management intends to finance operating costs over the next twelve months with existing cash on hand and loans from directors and/or private placement of common stock.

NOTE 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

<u>Basis of Presentation</u>

The financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America and are presented in US dollars. The Company has adopted a April 30 fiscal year end.

<u>Use of Estimates</u>

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates.

<u>Cash and Cash Equivalents</u>

The Company considers all highly liquid instruments purchased with a maturity of three months or less to be cash equivalents to the extent the funds are not being held for investment purposes.

<u>Fair Value of Financial Instruments</u>

ASC 820 "Fair Value Measurements and Disclosures" establishes a three-tier fair value hierarchy, which prioritizes the inputs in measuring fair value. The hierarchy prioritizes the inputs into three levels based on the extent to which inputs used in measuring fair value are observable in the market.

These tiers include:

Level 1: defined as observable inputs such as quoted prices in active markets;

Level 2: defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and

Level 3: defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.

The carrying value of cash and the Company's loan from shareholder approximates fair value due to their short-term maturity.

<u>Impairment of Long-Lived Assets</u>

The Company continually monitors events and changes in circumstances that could indicate carrying amounts of long-lived assets may not be recoverable. When such events or changes in circumstances are present, the Company assesses the recoverability of long-lived assets by determining whether the carrying value of such assets will be recovered through undiscounted expected future cash flows. If the total of the future cash flows is less than the carrying amount of those assets, the Company recognizes an impairment loss based on the excess of the carrying amount over the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or the fair value less costs to sell.

<u>Income Taxes</u>

The Company follows the liability method of accounting for income taxes. Under this method, deferred income tax assets and liabilities are recognized for the estimated tax consequences attributable to differences between the financial statement carrying values and their respective income tax basis (temporary differences). The effect on deferred income tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

<u>Revenue Recognition</u>

The Company will recognize revenue in accordance with Accounting Standards Codification No. 605, "Revenue Recognition" ("ASC-605"), ASC-605 requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured. Determination of criteria (3) and (4) are based on management's judgments regarding the fixed nature of the selling prices of the products delivered and the collectability of those amounts.

<u>Basic Income (Loss) Per Share</u>

The Company computes earnings (loss) per share in accordance with ASC 260-10-45 'Earnings per Share, which requires presentation of both basic and diluted earnings per share on the face of the statement of operations. Basic earnings (loss) per share is computed by dividing net earnings (loss) available to common stockholders by the weighted average number of outstanding common shares during the period. Diluted earnings (loss) per share gives effect to all dilutive potential common shares outstanding during the period. Dilutive earnings (loss) per share excludes al potential common shares if their effect is anti-dilutive. The Company has no potential dilutive instruments, and therefore, basic and diluted earnings (loss) per share are equal.

<u>Dividends</u>

The Company has not adopted any policy regarding payment of dividends. No dividends have been paid during the period presented.

<u>Intangible assets</u>

The accounting for costs associated with developing and populating an internet website differs in some respects from the guidance on other types of software development. ASC 350-50, Intangibles—Goodwill and Other—Website Development Costs, provides guidance on accounting for costs incurred in each of the five stages of website development. The stages of website development are:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. Planning

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. Application and infrastructure development

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. Graphical design development

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. Content development

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5. Operating

The Сompany developed the Website with Zoltaron Data Technics SDN. BHD.

As of April 30, 2022, the total amount of Website development was $2,950. Depreciation expense of the Website was $0 as of April 30, 2022.

<u>Recent Accounting Pronouncements</u>

The Company has reviewed all the recent accounting pronouncements issued to date of the issuance of these

financial statements and does not believe any of these pronouncements will have a material impact on the company other than those relating to Development Stage Entities discussed above.

NOTE 4 – COMMON STOCK

The Company has 75,000,000 common shares authorized with a par value of $0.001 per share.

On November 26, 2021 the Company issued 4,500,000 shares of its common stock at $0.001 per share for total proceeds of $4,500.

As of April 30, 2022, the Company had 4,500,000 shares issued and outstanding.

NOTE 5 – RELATED PARTY TRANSACTIONS

In support of the Company's efforts and cash requirements, it may rely on advances from related parties until such time that the Company can support its operations or attains adequate financing through sales of its equity or traditional debt financing. There is no formal written commitment for continued support by shareholders or directors. Amounts represent advances or amounts paid in satisfaction of liabilities. The advances were considered temporary in nature and were not formalized by a promissory note.

On November 26, 2021, the Company sold 4,500,000 shares of common stock at a price of $0.001 per share to its director.

NOTE 6. COMMITMENTS AND CONTINGENCIES

- Contractual commitments

The Company has entered into contractual payment commitments of $2,950 related to website development on January 16, 2022.

- Litigation

The Company was not subject to any legal proceedings during the period from September 20, 2021 (Inception) to April 30, 2022 and no legal proceedings are currently pending or threatened to the best of our knowledge.

NOTE 7 – SUBSEQUENT EVENTS

The Company has evaluated subsequent events from April 30, 2022 to the date the financial statements were issued and has determined that there are no items to disclose.

**Mag Magna Corp**

**FINANCIAL STATEMENTS**

**As of October 31, 2022** 

**INDEX TO AUDITED FINANCIAL STATEMENTS**

---

| | |
|:---|:---|
| *Balance Sheets as of October 31, 2022 (unaudited)* | *F-1* |
| *Statement of Operations for the period ended October 31, 2022 (unaudited)* | *F-2* |
| *Statement of Changes in Stockholder's Equity from July 31, 2022 to October 31, 2022 (unaudited)* | *F-3* |
| *Statement of Cash Flows for the period ended October 31, 2022 (unaudited)* | *F-4* |
| *Notes to the Financial Statements* | *F-5* |

---

MAG MAGNA CORP

BALANCE SHEETS

---

| | |
|:---|:---|
|  | &nbsp;&nbsp;October 31, 2022 (unaudited) |
| &nbsp;&nbsp;ASSETS |  |
| &nbsp;&nbsp;Current Assets |  |
| &nbsp;&nbsp;Checking/Savings |  |
| &nbsp;&nbsp;Сash and Cash Equivalents | &nbsp;&nbsp;4506 |
| &nbsp;&nbsp;Total Checking/Savings | &nbsp;&nbsp;4506 |
| &nbsp;&nbsp;Total Current Assets | &nbsp;&nbsp;4506 |
| &nbsp;&nbsp;Other Assets |  |
| &nbsp;&nbsp;Intangible Assets, net | &nbsp;&nbsp;2786 |
| &nbsp;&nbsp; Prepaid Expense | &nbsp;&nbsp;6450 |
| &nbsp;&nbsp;Total Other Assets | &nbsp;&nbsp;9236 |
| &nbsp;&nbsp;TOTAL ASSETS | &nbsp;&nbsp;13742 |
| &nbsp;&nbsp;LIABILITIES & EQUITY |  |
| &nbsp;&nbsp;Liabilities |  |
| &nbsp;&nbsp;Current Liabilities |  |
| &nbsp;&nbsp;Other Current Liabilities |  |
| Loan from Related Parties | &nbsp;&nbsp;16135 |
| &nbsp;&nbsp;Total Other Current Liabilities | &nbsp;&nbsp;16135 |
| &nbsp;&nbsp;Total Current Liabilities | &nbsp;&nbsp;16135 |
| &nbsp;&nbsp;Total Liabilities | &nbsp;&nbsp;16135 |
| &nbsp;&nbsp;Equity |  |
| &nbsp;&nbsp;Capital Stock | &nbsp;&nbsp;4500 |
| &nbsp;&nbsp;Retained Earnings | &nbsp;&nbsp;1 |
| &nbsp;&nbsp;Net Income | &nbsp;&nbsp;(6894) |
| &nbsp;&nbsp;Total Stockholders' deficit | &nbsp;&nbsp;(2393) |
| &nbsp;&nbsp;TOTAL LIABILITIES & STOCKHOLDER`S DEFICIT | &nbsp;&nbsp;13742 |

---

'

The accompanying notes are an integral part of these financial statements.

MAG MAGNA CORP

STATEMENT OF OPERATIONS

---

| | |
|:---|:---|
|  | July 31, 2022 – October 31, 2022<br> (unaudited) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Revenues | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- |
| Total Revenues |  |
| Operating Expenses |  |
| General and administrative expenses | 3600 |
| Bank service charges | 74 |
| Depreciation Expense | 164 |
| Total operating expenses | - |
| Net loss from operations | (3838) |
| Other Income | 2 |
| Provision for income taxes | - |
| <br> Net Income/Loss  | <br> (3836) |
| Loss per common share – Basic & Diluted | - |
| Weighted Average Number of Common Shares Outstanding-Basic & Diluted | 4500000 |

---

The accompanying notes are an integral part of these financial statements.

MAG MAGNA CORP

STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT)

FOR THE PERIOD FROM JULY 31, 2022 TO OCTOBER 31, 2022

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | Number of<br> common | Number of<br> common | Additional<br> Paid-in-<br> Capital | Accumulated<br> deficit | <br>Total |
| | Shares | Amount |  |  |  |
| Balance as of July 31, 2022 | 4500000 | $4500 | $- | $(3058) | $1442 |
| Net Income for the period<br> July 31, 2022 – October 31, 2022 | - | - | - | (3838) | (3059) |
| Balance as of October 31, 2022 | 4500000 | $4500 | $— | $(6894) | $(2393) |

---

The accompanying notes are an integral part of these condensed unaudited financial statements.

MAG MAGNA CORP

STATEMENTS OF CASH FLOWS

---

| | | |
|:---|:---|:---|
|  | &nbsp;&nbsp; July 31, 2022 – October 31, 2022<br> (unaudited) |  |
| &nbsp;&nbsp;**OPERATING ACTIVITIES** |  |  |
| &nbsp;&nbsp;Net Income | &nbsp;&nbsp;(3835) | &nbsp;&nbsp;$|
| &nbsp;&nbsp;Adjustments to reconcile Net Income <br> to net cash provided by operations: |  |  |
| &nbsp;&nbsp;Accounts Payable | &nbsp;&nbsp;(2950) |  |
| &nbsp;&nbsp;Prepaid Expense | &nbsp;&nbsp;6450 |  |
| &nbsp;&nbsp;Accumulated Deprication | &nbsp;&nbsp;164 |  |
| &nbsp;&nbsp;Cash Flows from Operating Activities | &nbsp;&nbsp;(171) |  |
| &nbsp;&nbsp;**FINANCING ACTIVITIES** |  |  |
| &nbsp;&nbsp;Capital Stock | &nbsp;&nbsp;- | &nbsp;&nbsp;$|
| &nbsp;&nbsp;Director's Loan | &nbsp;&nbsp;13074 |  |
| &nbsp;&nbsp;Cash Flows from Financing Activities | &nbsp;&nbsp;13074 |  |
| &nbsp;&nbsp;Net cash increase for period | &nbsp;&nbsp;3 |  |
| &nbsp;&nbsp;Cash at beginning of period | &nbsp;&nbsp;4503 |  |
| &nbsp;&nbsp;Cash at end of period | &nbsp;&nbsp;4506 | &nbsp;&nbsp;$|

---

The accompanying notes are an integral part of these condensed unaudited financial statements.

MAG MAGNA CORP

(A DEVELOPMENT STAGE COMPANY)

NOTES TO THE FINANCIAL STATEMENTS

NOTE 1 – ORGANIZATION AND DESCRIPTION OF BUSINESS

MAG MAGNA CORP ("the Company") was incorporated under the laws of the State of Wyoming, U.S. on September 20, 2021 (Inception). We are engaged in organizational activities and intend to expand company`s activities for distributing, marketing, and selling formula for feed additives development, using new technologies and elaborations in the near future.

NOTE 2 - GOING CONCERN

The financial statements have been prepared on a going concern basis which assumes the Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future.

MAG MAGNA CORP has incurred no loss since Inception (September 20, 2021) till April 30, 2022 and incurred accumulated loss of $6,894 for three months ended October 31, 2022 and further losses are anticipated in the development of its business. Accordingly, there is substantial doubt about the Company's ability to continue as a going concern.

The ability to continue as a going concern is dependent upon the Company generating profitable operations in the future and/or to obtain the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they come due. Management intends to finance operating costs over the next twelve months with existing cash on hand and loans from directors and/or private placement of common stock.

NOTE 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

<u>Basis of Presentation</u>

The financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America and are presented in US dollars. The Company has adopted a April 30 fiscal year end.

<u>Use of Estimates</u>

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates.

<u>Cash and Cash Equivalents</u>

The Company considers all highly liquid instruments purchased with a maturity of three months or less to be cash equivalents to the extent the funds are not being held for investment purposes. As of July 31, 2022 and October 31, 2022, our cash balances were $4,503 and $4,506.

<u>Fair Value of Financial Instruments</u>

ASC 820 "Fair Value Measurements and Disclosures" establishes a three-tier fair value hierarchy, which prioritizes the inputs in measuring fair value. The hierarchy prioritizes the inputs into three levels based on the extent to which inputs used in measuring fair value are observable in the market.

These tiers include:

Level 1: defined as observable inputs such as quoted prices in active markets;

Level 2: defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and

Level 3: defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.

The carrying value of cash and the Company's loan from shareholder approximates fair value due to their short-term maturity.

<u>Impairment of Long-Lived Assets</u>

The Company continually monitors events and changes in circumstances that could indicate carrying amounts of long-lived assets may not be recoverable. When such events or changes in circumstances are present, the Company assesses the recoverability of long-lived assets by determining whether the carrying value of such assets will be recovered through undiscounted expected future cash flows. If the total of the future cash flows is less than the carrying amount of those assets, the Company recognizes an impairment loss based on the excess of the carrying amount over the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or the fair value less costs to sell.

<u>Income Taxes</u>

The Company follows the liability method of accounting for income taxes. Under this method, deferred income tax assets and liabilities are recognized for the estimated tax consequences attributable to differences between the financial statement carrying values and their respective income tax basis (temporary differences). The effect on deferred income tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

<u>Revenue Recognition</u>

The Company will recognize revenue in accordance with Accounting Standards Codification No. 605, "Revenue Recognition" ("ASC-605"), ASC-605 requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured. Determination of criteria (3) and (4) are based on management's judgments regarding the fixed nature of the selling prices of the products delivered and the collectability of those amounts.

<u>Basic Income (Loss) Per Share</u>

The Company computes earnings (loss) per share in accordance with ASC 260-10-45 'Earnings per Share, which requires presentation of both basic and diluted earnings per share on the face of the statement of operations. Basic earnings (loss) per share is computed by dividing net earnings (loss) available to common stockholders by the weighted average number of outstanding common shares during the period. Diluted earnings (loss) per share gives effect to all dilutive potential common shares outstanding during the period. Dilutive earnings (loss) per share excludes al potential common shares if their effect is anti-dilutive. The Company has no potential dilutive instruments, and therefore, basic and diluted earnings (loss) per share are equal.

<u>Dividends</u>

The Company has not adopted any policy regarding payment of dividends. No dividends have been paid during the period presented.

<u>Intangible assets</u>

The accounting for costs associated with developing and populating an internet website differs in some respects from the guidance on other types of software development. ASC 350-50, Intangibles—Goodwill and Other—Website Development Costs, provides guidance on accounting for costs incurred in each of the five stages of website development. The stages of website development are:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11. Planning

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12. Application and infrastructure development

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13. Graphical design development

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14. Content development

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15. Operating

The Сompany developed the Website with Zoltaron Data Technics SDN. BHD. As of October 31, 2022, the total amount of Website development was $2,950. Depreciation expense of the Website was $164 as of October 31, 2022.

<u>Recent Accounting Pronouncements</u>

The Company has reviewed all the recent accounting pronouncements issued to date of the issuance of these financial statements, and does not believe any of these pronouncements will have a material impact on the company other than those relating to Development Stage Entities discussed above.

NOTE 4 – COMMON STOCK

The Company has 75,000,000 common shares authorized with a par value of $0.001 per share.

On November 26, 2021 the Company issued 4,500,000 shares of its common stock at $0.001 per share for total proceeds of $4,500.

As of July 31, 2022 and October 31, 2022, the Company had 4,500,000 shares issued and outstanding.

NOTE 5 – RELATED PARTY TRANSACTIONS

In support of the Company's efforts and cash requirements, it may rely on advances from related parties until such time that the Company can support its operations or attains adequate financing through sales of its equity or traditional debt financing. There is no formal written commitment for continued support by shareholders or directors. Amounts represent advances or amounts paid in satisfaction of liabilities. The advances were considered temporary in nature and were not formalized by a promissory note.

On November 26, 2021, the Company sold 4,500,000 shares of common stock at a price of $0.001 per share to its director. During the period from September 20, 2021 (inception) through October 31, 2022, the Company's sole director has loaned to the Company $13,074. This loan is unsecured, non-interest bearing and due on demand.

NOTE 6. COMMITMENTS AND CONTINGENCIES

- Contractual commitments

The Company has entered into contractual payment commitments of $2,950 related to website development on January 16, 2022 and $6,450 related to website development on October 26, 2022.

- Litigation

The Company was not subject to any legal proceedings during the period from September 20, 2021 (Inception) to October 31, 2022 and no legal proceedings are currently pending or threatened to the best of our knowledge.

NOTE 7. PREPAID EXPENSES

As of October 31, 2022, prepaid expenses were $6,450 and consist of prepaid website development related to Zoltaron Data Technics SDN. BHD.

NOTE 8 – SUBSEQUENT EVENTS

The Company has evaluated subsequent events from October 31, 2022 to the date the financial statements were issued and has determined that there are no items to disclose.

**Part II**

**INFORMATION NOT REQUIRED IN PROSPECTUS**

**Item 13. Other Expenses of Issuance and Distribution.**

Expenses incurred or (expected) relating to this Prospectus and distribution are

as follows:

---

| | |
|:---|:---|
| SEC Registration Fee | $15 |
| Auditor Fees and Expenses | $9500 |
| Legal Fees and Expenses | $1200 |
| **TOTAL** | $10715 |

---

All amounts are estimates, other than the SEC's registration fee.

 **Item 14. Indemnification of Directors and Officers.**

Bylaws of Mag Magna allow for the indemnification of the officer and/or director in regards each such person carrying out the duties of his or his office. The Board of Directors will make determination regarding the indemnification of the director, officer or employee as is proper under the circumstances if he has met the applicable standard of conduct set forth under the Wyoming Revised Statutes.

As to indemnification for liabilities arising under the Securities Act of 1933, as amended, for a director, officer and/or person controlling Mag Magna Corp, we have been informed that in the opinion of the Securities and Exchange Commission such indemnification is against public policy and unenforceable.

**Item 15. Recent sales of unregistered securities** 

Since inception, the Registrant has sold the following securities that were not registered under the Securities Act of 1933, as amended.

**Name and Address Date Shares Consideration** 

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;**Name** | &nbsp;&nbsp;**Date** | &nbsp;&nbsp;**Shares** | &nbsp;&nbsp;**Consideration** |
| &nbsp;&nbsp;Oleg Bilinski | &nbsp;&nbsp;November 26, 2021 | &nbsp;&nbsp;4500000 | &nbsp;&nbsp;$4500 |

---

We issued the foregoing shares of common stock to our sole officer and director pursuant to Section 4(2) of the Securities Act of 1933. He is a sophisticated investor, is our sole officer and director, and is in possession of all material information relating to us. Further, no commissions were paid to anyone in connection with the sale of the shares and general solicitation was not made to anyone.

**Item 16. Exhibits**

See Exhibit Index attached to this registration statement, which is incorporated by reference herein.

**Item 17. Undertakings.**

The undersigned registrant hereby undertakes to provide to the underwriters, at the closing specified in the underwriting agreement, certificates in such denominations and registered in such names as required by the underwriters to permit prompt delivery to each purchaser.

Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

The undersigned hereby undertakes that:

(1) For purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant to Rule 424(b)(1) or (4) or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective.

(2) For the purpose of determining any liability under the Securities Act, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

**Exhibit Index**

---

| | |
|:---|:---|
| **EXHIBIT<br> NUMBER** | **DESCRIPTION OF EXHIBIT** |
| &nbsp;&nbsp;&nbsp;&nbsp;3.1\* | [Articles of Incorporation](https://www.sec.gov/Archives/edgar/data/1949864/000194986422000002/articles3_1.htm) |
| &nbsp;&nbsp;&nbsp;&nbsp;3.2\* | [Bylaws](https://www.sec.gov/Archives/edgar/data/1949864/000194986422000002/bylaws3_2.htm) |
| &nbsp;&nbsp;&nbsp;&nbsp;5.1\* | [Opinion of Attorney](https://www.sec.gov/Archives/edgar/data/1949864/000194986422000002/opinion5_1.htm) |
| &nbsp;&nbsp;&nbsp;&nbsp;23.1 | [Consent of Auditing Firm](consent23_1.htm) |
| &nbsp;&nbsp;&nbsp;&nbsp;10.1\* | [Loan Agreement as of December 2, 2021](https://www.sec.gov/Archives/edgar/data/1949864/000194986422000002/loanagreement10_1.htm) |
| 10.2<br>| [Patent License and Assignment Agreement](ex10_2.htm) |
| 99.1\*<br>| [Subscription Agreement](https://www.sec.gov/Archives/edgar/data/1949864/000194986422000002/subscription99_1.htm) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 99.2<br>99.3<br>99.4<br>99.5 | [Registration certificate MAGA](ex99_2.htm) <br> [Registration certificate CHASIS](ex99_3.htm)<br>[Appendix to Registration certificate of MAGA](ex99_4.htm)<br>[Appendix to Registration certificate of CHASIS](ex99_5.htm) |
| 107\* | [EX-FILING FEES](https://www.sec.gov/Archives/edgar/data/1949864/000194986422000002/exfilingfees107.htm) <br> \*- The documents were previously filed on November 25, 2022. |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized on January 30, 2023.

---

| | |
|:---|:---|
| Mag Magna Corp | Mag Magna Corp |
| By: | /s/ Oleg Bilinski |
|  | Oleg Bilinski |
|  | Director, President, Chief Executive Officer, Treasurer, and Secretary<br> (Principal Executive, Financial and Accounting Officer) |

---

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

---

| | |
|:---|:---|
| By: | /s/ Oleg Bilinski |
|  | Oleg Bilinski |
|  | Director, President, Chief Executive Officer, Treasurer, and Secretary<br> (Principal Executive, Financial and Accounting Officer) |

---

## Exhibit 10.2

**PATENT LICENSE AND ASSIGNMENT AGREEMENT**

Patent License and Assignment Agreement (this "Agreement") is entered into as of November 15, 2022 (the "Effective Date") by and between Ipax LLC («Assignor»), and Mag Magna Corp. («Assignee»), (herein individually referred to as a "Party" and collectively referred to as the "Parties").

RECITALS

**WHEREAS**, Assignor owns certain patents related to veterinary medicinal products, feed additives, premixes and finished feeds, namely a formula of feed additives (the "Assigned Patent Rights");

**WHEREAS**, Assignor has the right to assign Assigned Patent Rights as defined below;

**WHEREAS**, Assignor agrees to provide Assignee a chemical formula of feed additives and advisory services related to the assigned products subject to the terms and conditions for such assignment as set out in this Agreement;

**WHEREAS,** Assignee believes it must own Assigned Patent Rights to effectively raise funds to distribute and market products, and consequently Assignee desires to acquire title to Assigned Patent Rights, subject to the terms and conditions for such assignment as set out in this Agreement;

**WHEREAS,** Assignee seeks to obtain an exclusive right to practice Assigned Patent Rights, and consequently Assignor desires to grant such an exclusive right to Assignee under the terms of this Agreement; and

**WHEREAS**, the Parties desire during the term of this Agreement grant to Assignee Assigned Patent Rights.

**1. DEFINITIONS AND INTERPRETATION** 

**1.1 <u>Glossary of Terms.</u>**

a) In this Agreement, the following words shall, unless otherwise stated or are inconsistent with the context, have the following meanings:

**• "Agreement"** means this Patent License and Assignment Agreement, entered into between Assignor and Assignee on November 15, 2022.

**• "Assigned Patent Rights"** means the rights and interests in and to any and all assigned patents (including Assignor's certificates and formulas), including any and all continuing applications, renewals, and all letters patent on any of the foregoing.

**• "Effective Date"** means the date of this Agreement agreed to by the Parties as the date on which the Agreement takes effect.

**• "Field of use"** is a provision based on a patent license that limits the scope of what the Assignor authorizes to the Assignee that manufactures a patented product or performs a patented process to do in relation to the patent, by specifying a defined field of use that is, a defined field of permissible operation by the Assignor.

**• "License"** means any rights under this Agreement now or hereafter acquired by Assignee to use any registration, copyright, or copyright registration for which a patent is in existence or other licenses of rights or interests now held or hereafter acquired by Assignee.

**• "Patents"** means the ownership of all rights, title, and interest in and to each of the Patents hereafter acquired by Assignee, free and clear of all liens and other adverse claims. All of the issued Patents are currently in compliance with formal legal requirements (including payment of filing, examination, and maintenance fees and proofs of working or use), are valid and enforceable, and are not subject to any maintenance fees or taxes, or actions falling. No Patent has been or is now involved in any interference, reissue, reexamination, or opposition proceeding.

**• "Product"** means any Product made or commercialized by or for Mag Magna Corp. in any country or territory in the world (or any component thereof).

**• "Term"** means the period in which the Agreement shall be in full force and effect, commencing on the Effective Date and continuing for a term of 5 (five) years.

**• "Territory"** means all the countries and territories within North America.

**2. COMMENCEMENT AND DURATION**

**2.1 <u>Commencement of Agreement</u>**. This Agreement shall commence on the Effective Date and shall continue for a term of 5 (five) years and may be prolonged for any applicable period terminated in accordance with the termination provisions.

**2.2 <u>Agreement exclusivity</u>**. The Parties agree that this Agreement is entered into on an exclusive basis. According to this Agreement, Assignor transfers to Assignee an exclusive right for distributing, developing, marketing, and selling CHASIS and MAGA components.

**3. CONFIDENTIALITY**

**3.1 <u>Confidentiality of Terms.</u>** The Parties hereto will keep the terms and existence of this Agreement and the identities of the Parties hereto and their affiliates confidential and will not now or hereafter divulge any of this information to any third party except (a) with the prior written consent of the other party; (b) as otherwise may be required by law or legal process, including, without limitation, in confidence to legal and financial advisors in their capacity of advising a party in such matters;(c) during the course of litigation, so long as the disclosure of such terms and conditions is restricted in the same manner as is the confidential information of other litigating Parties;(d) in confidence to its legal counsel, accountants, banks and financing sources and their advisors solely in connection with complying with its obligations under this Agreement; (e) by Assignee, in order to perfect Assignee's interest in the Assigned Patent Rights; (f) to enforce Assignee's right, title, and interest in and to the Assigned Patent Rights; provided that, in (b) through (d) above, (i) to the extent permitted by law, the disclosing party will use all legitimate and legal means available to minimize the disclosure to third Parties, including, without limitation, seeking a confidential treatment request or protective order whenever appropriate or available; and (ii) the disclosing party will provide the other party with at least ten (10) days' prior written notice of such disclosure.

**4. REVIEW AND CONDITIONS** 

**4.1 <u>Termination and Survival</u>.** In the event all conditions set forth in this Agreement are not met within sixty (60) days following the Effective Date, Assignee will have the right to terminate this Agreement.

**4.2 <u>Territory.</u>** The territory of the Assigned Patent Rights is North America. It is also possible to expand the geographical boundaries by additional signed Agreement by both parties in case it will not contradict them and will not cause any damage to the business.

**5. PAYMENT CONSIDERATION AND TERMS**

**5.1**  **<u>Payment terms</u>.** All royalty payments to Assignor shall be made at the end of the reporting period of the company by the Assignee. Payment of royalties shall be made to Assignor not later than the fourteenth (14th) day after the end of the period to which the payment relates. The Assignee is not obligated to make any minimum royalty payments hereunder. The amount payable shall not comprise the funds raised in the initial public offering of Mag Magna Corp.

**5.2 <u>Royalty Payment</u>.** For the rights granted in this Agreement, and subject to Paragraph 4 herein, Assignee shall pay Assignor a royalty of twenty percent (20%) of Assignee's product sale manufactured, sold, or imported by Assignee in the Territory.

**5.3 <u>Termination of Royalty on Invalidity or Unenforceability</u>.** The royalty payments shall terminate if the Patents are held invalid or unenforceable. The Patents shall be deemed invalid or unenforceable under this Agreement if a court or tribunal of competent jurisdiction makes such a determination, and the determination becomes final in that it is not further reviewable through appeal or exhaustion of all permissible petitions or applications for rehearing or review.

**6. TRANSFER OF PATENTS AND ADDITIONAL RIGHTS**

**6.1 <u>Assignment of Patents.</u>** Upon the Effective Day, Assignor hereby assigns, transfers, and conveys to Assignee the exclusive right, title, and interest in the Assigned Patent Rights.

**6.2 <u>License of Assigned Patent Rights to Assignee</u>.** Subject to the terms and conditions hereof, Assignor hereby grants to Assignee the exclusive right and license to the Assigned Patent Rights, solely for use within the terms stated in this Agreement, to (i) distribute, market and offer for sale and sell products and services under the Assigned Patent Rights, and (ii) make improvements to Assigned Patent Rights and further distribute, market and offer for sale and sell products and services to Assigned Patent Rights. Assignee agrees to maintain the quality and performance of any products or services under Assigned Patent Rights or improvements thereto, at a level that meets or exceeds standards of quality and performance generally accepted in the industry.

**6.4 <u>Registration Certificates</u>**. Assignee desires to obtain copies of the registration certificates to the Assigned Patent Rights in connection with its business, and Assignor desires to grant such registration certificates on the terms and conditions contained herein solely in the Field of use.

**7.** **REPRESENTATIONS AND WARRANTIES OF ASSIGNOR**

Assignor hereby represents and warrants to Assignee as follows that, as of the Effective Date:

**7.1 <u>Authority</u>.** Assignor has the full power and authority and has obtained all third-party consents, approvals, and/or other authorizations required to enter into this Agreement and to carry out its obligations hereunder, including, without limitation, the assignment of Assigned Patent Rights to Assignee.

**7.2 <u>Title and Contest</u>.** Assignor owns all right, title, and interest to the Assigned Patent Rights, including, without limitation**,** all right, title, and interest to sue for infringement of the Patents. Assignor has obtained and properly recorded previously executed assignments for the Patents as necessary to fully perfect its rights and title therein in accordance with governing law and regulations in each respective jurisdiction. Assigned Patent Rights are free and clear of all liens, claims, mortgages, security interests or other encumbrances, and restrictions. There are no actions, suits, investigations, claims, or proceedings threatened, pending, or in progress relating in any way to the Assigned Patent Rights.

**7.3 <u>Restrictions on Rights</u>.** Assignee will not be subject to any covenant not to sue or similar restrictions on its enforcement or enjoyment of Assigned Patent Rights as a result of any prior transaction related to the Assigned Patent Rights.

**7.4 <u>Conduct</u>.** To Assignor's knowledge formed after reasonable due diligence and investigation, Assignor or its representatives have not engaged in any conduct, or omitted to perform any necessary act, the result of which would invalidate any of the Patents or hinder their enforcement, including, without limitation, misrepresenting Assignor's patent rights to a standard-setting organization.

**7.5 <u>Enforcement</u>.** Assignor has not put a third party on notice of actual or potential infringement of any of the Patents. Assignor has not invited any third party to enter into a license under any of the Patents. Assignor has not initiated any enforcement action with respect to any of the Patents.

**7.6 <u>Further Cooperation</u>.** At the reasonable request of Assignee, Assignor will perform such acts and things as may be necessary or desirable for effecting completely the consummation of the transactions contemplated hereby, including, without limitation, execution, acknowledgment, and recordation of other such papers. In addition, Assignor will continue to prosecute, maintain, and defend the Patents at its sole expense until the end of this Agreement.

**8. REPRESENTATIONS AND WARRANTIES OF ASSIGNEE**

Assignee hereby represents and warrants to Assignor as follows that, as of the Effective Date:

**8.1 <u>Valid Existence and Good Standing</u>**. Assignee is a corporation duly formed, validly existing, and in good standing under the laws of the jurisdiction of its formation.

**8.2 <u>Assurance</u>**. Assignee has all requisite power and authority to (i) enter into, execute, and deliver this Agreement and (ii) perform fully its obligations hereunder.

**9. MISCELLANEOUS MATTERS** 

**9.1 <u>Construction.</u>**<u> </u>This Agreement has been negotiated by the Parties and will be interpreted fairly in accordance with its terms and without any strict construction in favor of or against either Party, including without limitation, no provision of this Agreement shall be construed against or interpreted to the disadvantage of any Party hereto by any court or other governmental authority by reason of such Party's having or being deemed to have structured or drafted such provision.

**9.2 <u>Relationship of Parties.</u>** The Parties agree that they are acting as independent contractors and not as partners or joint venturers, and under no circumstances shall any of the employees of one Party be deemed the employees of the other for any reason or purpose. This Agreement shall not be construed as authority for either party to act for the other Party in any agency or other capacity, or to make commitments of any kind for the account of or on behalf of the other.

**9.3 <u>Modification; Waiver.</u>**<u> </u>Any modification or waiver of this Agreement or parts of this Agreement must be in writing, specifically referencing this Agreement, and signed by an authorized representative of the party against whom enforcement of the purported modification or waiver is sought. Any failure to exercise any right, remedy or option or any other waiver by any party of a breach of any provision of this Agreement shall not operate as or be construed to be a waiver of any other breach of that provision or of any breach of any other provision of this Agreement.

**IN WITNESS WHEREOF**, each of the Parties hereto has caused this Agreement to be duly executed as of the day and year first above written.

**«Assignor»**

---

| | |
|:---|:---|
| &nbsp;&nbsp;Name | &nbsp;&nbsp;Ipax LLC ("Ipax") |
|  | &nbsp;&nbsp;Ipax LLC |
| &nbsp;&nbsp;Head office | &nbsp;&nbsp;30 N Gould St Ste R Sheridan, WY 82801 |
| &nbsp;&nbsp;EIN | &nbsp;&nbsp;92-1040002 |

---

**«Assignee»**

---

| | |
|:---|:---|
| &nbsp;&nbsp;Name | &nbsp;&nbsp;Mag Magna Corp |
| &nbsp;&nbsp;Head office | &nbsp;&nbsp;325 W Washington St, Ste 2877 |
|  | &nbsp;&nbsp;San Diego, CA 92103 |
| &nbsp;&nbsp;EIN | &nbsp;&nbsp;98-1626237 |

---

Signed by Ipax LLC («Assignor»): ___________________________

Signed by Mag Magna Corp («Assignee»): ____________________________

## Exhibit 23.1

**CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

We hereby consent to the incorporation in this Registration Statement on Form S-1 of our report dated November 25, 2022, relating to the financial statements of Mag Magna Corp as of April 30, 2022 and the period from September 20, 2021 (Inception) through April 30, 2022 and to all references to our firm included in this Registration Statement.

Certified Public Accountants

Lakewood, CO

January 30, 2023

## Exhibit 99.2

STATE SERVICE OF UKRAINE ON FOOD SAFETY AND CONSUMER PROTECTION

REGISTRATION CERTIFICATE

Pursuant to the Law of Ukraine "On Veterinary Medicine", Resolution of the Cabinet of Ministers of Ukraine dated November 21, 2007 No. 1349 "On Approval of the Provisions on State Registration of Veterinary Medical Products, Feed Additives, Premixes and Finished Feeds" and on the basis of Expert Opinion No. 383-К/06 dated February 13, 2019, recommendations of the State Pharmacological Commission of Veterinary Medicine, Order of the State Service of Ukraine on Food Safety and Consumer Protection No. 135 dated March 4, 2019, the following is registered:

product: "MAGA"

form: Concentrated liquid

Holder of the registration certificate:

LLC "IPAX-UKRAINE"

вул. Velika Vasylkivska, bldg. 29/31, office 103, Kyiv, 01004, UKRAINE

registered in Ukraine under No. АВ-08263-04-19 dated March 4, 2019

Producer:

JSC "FACTORY "COMBI"

вул. Kyivska str., 29, village Pirnove, Vyshhorod District, Kyiv Region, 07342, UKRAINE

In case of any changes made to the registration dossier, the certificate holder (producer) shall notify the registration authority.

Mandatory appendices:

- brief description of the product (Appendix 1);

- label (Appendix 2).

Registration certificate is valid until: March 3, 2024

This certificate is not an obligation for the purchase of this product.

/*Seal:*/ *STATE SERVICE OF UKRAINE ON FOOD SAFETY AND CONSUMER PROTECTION*

*Identification code 39924774*

*/National emblem of Ukraine/*

*No. 1*/

Director of Department for Food Safety and Veterinary Medicine /*Signature*/ B. I. Kobal

## Exhibit 99.3

STATE SERVICE OF UKRAINE ON FOOD SAFETY AND CONSUMER PROTECTION

REGISTRATION CERTIFICATE

Pursuant to the Law of Ukraine "On Veterinary Medicine", Resolution of the Cabinet of Ministers of Ukraine dated November 21, 2007 No. 1349 "On Approval of the Provisions on State Registration of Veterinary Medical Products, Feed Additives, Premixes and Finished Feeds" and on the basis of Expert Opinion No. 384-К/06 dated February 13, 2019, recommendations of the State Pharmacological Commission of Veterinary Medicine, Order of the State Service of Ukraine on Food Safety and Consumer Protection No. 135 dated March 4, 2019, the following is registered:

product: "CHASIS"

form: Concentrated liquid

Holder of the registration certificate:

LLC "IPAX-UKRAINE"

Velika Vasylkivska, bldg. 29/31, office 103, Kyiv, 01004, UKRAINE

registered in Ukraine under No. АВ-08263-04-19 dated March 4, 2019

Producer:

JSC "FACTORY "COMBI"

Kyivska str., 29, village Pirnove, Vyshhorod District, Kyiv Region, 07342, UKRAINE

In case of any changes made to the registration dossier, the certificate holder (producer) shall notify the registration authority.

Mandatory appendices:

- brief description of the product (Appendix 1);

- label (Appendix 2).

Registration certificate is valid until: March 3, 2024

This certificate is not an obligation for the purchase of this product.

/*Seal:*/ *STATE SERVICE OF UKRAINE ON FOOD SAFETY AND CONSUMER PROTECTION*

*Identification code 39924774*

*/National emblem of Ukraine/*

*No. 1*/

Director of Department for Food Safety and Veterinary Medicine /*Signature*/ B. I. Kobal

## Exhibit 99.4

Appendix 1

To Registration Certificate АВ-08262-04-19

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dated March 4, 2019

**"MAGA"**

(immunostimulant for oral use)

Product leaflet

**Composition:**

1 ml of the product contains active ingredients (%):

Magnesium chloride — 41.0

Extracts — 10.0

wheat sprouts; nettle; amaranth; wormwood.

Inactive ingredients: purified treated water.

**Pharmaceutical form:** 

Liquid oil-like liquid of light brown to dark brown color, slightly detectable smell of herbs. pH of -2+\-0.5.

**Pharmacological properties:**

Magnesium chloride is an environmentally friendly mineral of natural origin with a bactericidal effect. Magnesium performs various functions in animal organisms. It is involved in supporting the normal acid-base balance and osmotic pressure in body fluids and tissues, and also provides the functional ability of the neuromuscular apparatus. Magnesium is a component of enzymes, it also regulates oxidative processes and is involved in thermoregulation. Magnesium is an intrinsic cation, found in the mitochondria of cells and participating in the process of intermediate metabolism as a specific activator or cofactor of a number of enzyme systems. Magnesium ion is involved in the assimilation and metabolism of energy, carbohydrates, fats, protein biosynthesis, influencing the state of nonspecific immunity, excitability of nerve endings, muscle contraction and skeletal calcification processes. .

The unique formula of "MAGA" has a bactericidal effect against gram-negative and gram-positive microorganisms, eliminates inflammatory processes in the gastrointestinal tract (including the oviduct in laying hens), inhibits toxic phenomena, preventing the accumulation of toxins from feed, has a general stimulating, tonic, adaptogenic and anti-stress effect.

The selected formulation, namely the composition of extracts: sprouts of wheat, wormwood, amaranth, nettle, magnesium chloride, etc., ensures normalization of metabolism in farm animals and poultry, improves the overall body resistance, regeneration of mucous membranes, increases the intensity and prolongation of egg production in laying hens, stimulates the digestive system, supplements the ovary of laying hens with macro- and microelements necessary for reproduction, increases the processes of poultry and animal weight formation, has hepatoprotective properties.

**Application:**

FA "MAGA" is used to increase the absorption of nutrients, eliminate intoxication, stimulate and normalize metabolism, increase the overall body resistance, reduce the effects of stress factors, normalize digestive processes.

**Dosage:**

The product is administered by watering with drinking water at the rate of 300 ml to 2500 ml of the product per 1000 liters of drinking water through the watering system.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*For preventive purposes*, the product is used within 7 days in doses:

Laying breed hens — ***300ml-1000ml*** per 1,000 liters of drinking water

Broiler chickens — ***300ml-2000ml*** per 1,000 liters of drinking water.

Turkeys — **300ml-2500ml** per 1,000 liters of drinking water.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The working solution of the product must be prepared before use.

**Contraindications:**

None.

**Presentation form:**

Polymeric containers with a volume of 1l, 5l, 10l.

**Storage**

In a dry dark place away from children at temperatures from 5 to 40 °C.

Shelf life: 36 months

**Holder of the registration certificate:** 

LLC "IPAX-UKRAINE", 01004,

. Kyiv, Velika Vasylkivska, bldg. 29/31, office 103

Mobile: +38 (099) 00 45 111; +38 (068) 00 45 111;

E-mail: <u>ipaxukr@gmail.com</u>

## Exhibit 99.5

Appendix 1

To Certificate of Registration АВ-08263-04-19

&nbsp;&nbsp;&nbsp;&nbsp;Dated March 4, 2019

**"CHASIS"**

(intestinal microflora stabilizer, for oral use)

**Product leaflet**

**Composition:**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1 ml of the product contains active ingredients (%):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Wormwood extract — 7.0

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amaranth extract — 1.0

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inactive ingredients: — 0.5

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;mixture of salts in terms of the equivalent amount of ammonium chloride.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Purified treated water.

**Pharmaceutical form:**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sterile opaque liquid of light straw greenish color. A slight sediment is possible, however, it does not reduce the product activity and disappears when shaken, with a distinctive odor, pH of -7.1 +\-0.03

**Pharmacological properties:**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The "CHASIS" feed additive is an active substance consisting of alkaloids obtained by the extraction of medicinal plants, which is a source of natural phyto components that are absorbed by 95-98%. Unique properties of the formulation improve performance in monogastric animals and poultry.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;It normalizes the functioning of the gastrointestinal tract and microflora. It restores the optimal pH value in the gastrointestinal tract, increases body resistance to infections and toxin buildup, has anti-inflammatory, antiseptic and hepatoprotective properties. It has an antimicrobial effect on (Staphylococcus aureus; E.coli;Salmonella enteritidis; Salmonella pullorum gallinarun; Proteus vulgaris; Klebsiella pneumoniae; Pseudomonas aeruginosa; Campylobacter jejuni; Clostridium perfringens;Clostridium botulinum;Actinabacillus pleuropneumoniae; Bordetella bronchiseptica;Enterococcus hirae; Mycoplasma gallispticum (MS/MM/MI);Treponema hyodysenteriae; Bacillus anthracis; Mycobacterium tuberculosis;, has a virucidal effect (DNA- and RNA-viruses - causative agents of Newcastle, Gumboro, Marek's, Teschen diseases, circovirus infection, infectious rhinotracheitis, avian influenza virus H7N1, avian influenza virus H5N1, egg production decline syndrome virus, etc.), eliminates feed losses and improves its digestibility, increases adsorption of amino acids. It reduces oviduct inflammation (for laying hens), has an anthelmintic effect. It prevents oxidation of fats, fatty acids and sterols that may contribute to toxicosis. It improves general health of poultry, enhances feed conversion, egg production. The "CHASIS" feed additive contains no genetically modified substances.

**Application:**

The use of feed additives increases the performance and health of animals and poultry. The intestinal tract health plays an important role in this, as it is an important organ where the immunological protection of the body begins, and all nutrients are absorbed. Also, the gastrointestinal tract is a place where pathogens of infectious diseases (Clostridium sp, E.coli, Salmonella sp., etc.) proliferate. This ecosystem may be the weakest link in the immune system. Thus, the active ingredients of the feed additive are aimed at maintaining stable intestinal activity and function. It helps to control the action of numerous pathogens and stress factors. The use of FA "CHASIS" provides a more reliable effect of body protection. Active ingredients are absorbed and preserve reproduction and growth. The integrity of the intestinal barrier is preserved, the absorption of nutrients is improved. The negative effect caused by toxins, parasites, infectious agents is minimized.

The additive is used throughout the entire rearing period. It increases the efficiency of feeding and absorption of feed. It is used in the period of stress and prevention of infectious diseases, to optimize the absorption of nutrients, improves the adsorption of amino acids and reduces the number of mediators of inflammatory processes.

**Dosage**: FA "CHASIS" is used in livestock and poultry farming, by watering with drinking water at the rate of **150 ml to 400 ml** of the product per **1,000 liters** of drinking water, through a dispenser, within **7 days**. It must be used in diluted form only. The solution of the product must be prepared before use.

**Contraindications: None.** 

**Presentation form:** Polymeric containers with a volume of 1l, 5l, 10l. 20l, 200l.

**Storage:** In a dry dark place away from children at temperatures from 5 to 40°C.<br> Shelf life:36 months

**Holder of the registration certificate:** 

LLC "IPAX-UKRAINE", 01004,

. Kyiv, Velika Vasylkivska, bldg. 29/31, office 103;

Mobile: +38 (099) 00 45 111: +38 (068) 00 45 111 :

E-mail: ipaxukr@gmail.com

**Producer**: LLC "IPAX-UKRAINE"

## Corresp

***<u>Via EDGAR Transmission</u>***

January 30, 2023

Oleg Bilinski

Chief Executive Officer

Mag Magna Corp.

325 W Washington St.,

Ste 2877 San Diego,

CA 92103

**Re: Mag Magna Corp.** 

**Registration Statement on Form S-1** 

**Filed November 25, 2022** 

**File No. 333-268561**

Ladies and Gentlemen:

Set forth below are the responses of Mag Magna Corp. (the "***Company***," "***we***," "***us***" or "***our***") to comments received from the staff of the Division of Corporation Finance (the "***Staff***") of the Securities and Exchange Commission (the "***Commission***") by letter dated December 22, 2022, with respect to the Company's Registration Statement on Form S-1, File No. 333-268561, initially filed with the Commission on November 25, 2022 (the "***Registration Statement***").

Concurrently with the submission of this letter, we are filing through EDGAR Amendment No. 1 to the Registration Statement ("***Amendment No. 1***").

For your convenience, each response is prefaced by the exact text of the Staff's corresponding comment in bold, italicized text. All references to page numbers and captions correspond to Amendment No. 1 unless otherwise specified. Unless indicated otherwise, capitalized terms used, but not defined, herein shall have the meaning given to them in the Registration Statement.

**<u>Registration Statement on Form S-1</u>**

**Cover Page**

***1. On the cover page of your registration statement, we note you have checked that you qualify only as a smaller reporting company. However, on page 23, you provide a risk factor that has language as if you are an emerging growth company. Please reconcile. See Rule 12b-2 of the Exchange Act for guidance.***

<u>Response</u>:

We are an "emerging growth company" as defined in the Jumpstart Our Business Startups Act ("JOBS Act").

*We are an "emerging growth company" under the JOBS Act…, page 21*

The risk factor appeared to be irrelevant and was removed.

***2. Please revise your disclosure regarding the termination of the offering to provide a specific date, rather than tying the termination to the effective time of the prospectus. See Item 501(b)(iii) of Regulation S-K.***

<u>Response</u>:

With all due respect, we cannot provide a specific date of the termination of the offering as we are not able to determine with accuracy when the formal review of our Registration Statement is completed and we become eligible to offer the sale of shares.

*The shares will be offered at a fixed price of $0.025 per share for a period of three hundred and sixty-five (365) days from the effective date of this prospectus.*

**Prospectus Summary** 

**Overview, page 5**

***3. We note your disclosure on the cover page that you have been involved primarily in organizational activities to date and do not have sufficient capital to commence operations. However, in the Prospectus Summary, MD&A and Business sections you state that you are "engaged in developing, marketing, and selling" formula for feed additives development, along with other activities. Please revise your disclosure throughout the prospectus to clarify that the company has engaged in only organizational activities to date and that the other activities that are disclosed are aspirational at this time.***

<u>Response</u>:

The Company has revised the information throughout the prospectus. As per today we have been involved primarily in organizational activities and are planning to expand our activities for marketing, and selling formula for feed additives development. Moreover, as of November 15, 2022 the Company signed a Patent License and Assignment Agreement with Ipax LLC stating the assignment of the rights to the patents. The Company has filled the Agreement as an Exhibit 10.2.

***4. Please remove your statement that Mag Magna is "an advanced company in the field of industrial cultivation", as the company has engaged only in organizational activities to date and has not yet commenced operations.***

<u>Response</u>:

The Company has removed the requested statement.

*Mag Magna Corp is founded on an innovative approach…, page 6*

***5. We note your disclosure throughout the prospectus that you plan to submit an investigational new drug application (IND) to the FDA. We also note disclosure that you will submit a new drug application (NDA) to the FDA prior to marketing your products. Please revise the Prospectus Summary to provide a brief overview of the regulatory regime applicable to the company's products, including a discussion of any preclinical and clinical studies that will be required prior to commercialization and revenue generation. Please also expand your Government Regulation and Product Approval section on page 33 to include a detailed discussion of the applicable regulations, including specifics about how the feed additives industry is regulated in the U.S.***

<u>Response</u>:

As of now, we are fully engaged in organizational operations. The Company has revised the information concerning submitting an IND and NDA to FDA throughout the prospectus. Also, the Company has expanded the statement regarding Government Regulation and further Product Approval. The Company expects to submit the application to the FDA in the future. However, now we primarily focus on networking and exploring the possibilities for cooperation with our future partners. Please see page 32.

***6. We note the properties listed for MAGA and the discussion of CHASIS on page 5. Please revise your disclosure to provide support for the claims made regarding the performance of each formula.***

<u>Response</u>:

The Company has expanded the description of the chemical properties of both products. Also, registration certificates and Appendix to Registration certificates of MAGA and CHASIS are filed as Exhibits 99.2-99.5.

***7. We note your statements that Ipax has "successfully registered" both MAGA and CHASIS in Eastern Europe and received a certificate. Please expand your disclosure to explain what the referenced registration process entailed and what the certificate signifies. Please also discuss any preclinical and/or clinical studies conducted by Ipax to date. In addition, clarify what you mean when you state that Ipax "successfully entered" the Eastern European market.***

<u>Response</u>:

Registration certificates for MAGA and CHASIS were approved and received in Ukraine after conducting clinical trials. Both registration certificates and Appendix to Registration certificates of MAGA and CHASIS are filed as Exhibits 99.2-99.5.

**Our Growth Strategy, page 7**

***8. We note your mention of "existing facilities" on pages 7 and 32. Please revise your disclosure to provide more detail regarding these facilities***

<u>Response</u>:

The Company has amended the disclosure. Please see pages 8 and 31.

***9. We note your disclosure regarding the work of your "operations team" on page 7; however, we also note that the company has only one employee, Oleg Bilinski. Please reconcile.***

<u>Response:</u>

The Company has revised the information.

***10. We note your statement on pages 7 and 32 that the Company aims to coordinate with "the partners" to continually develop new products and processes. Please revise to explain who "the partners" are and provide the terms of any materials relationships and agreements.***

<u>Response:</u>

The Company intends to cooperate with potential companies engaged in feed additives distribution and poultry cultivation. As of the date of the Prospectus, we have not engaged in any material relationships with any partners.

*The Company aims to coordinate with the partners to continually develop processes that …, page 8*

**Risk Factors**

**We may be unable to retain our existing customers or attract new customers …, page 11**

***11. We note the above-entitled risk factor which discusses the retention of existing customers. However, we also note your disclosure that the company has engaged in only organizational activities to date and has not had funds to commence operations. Therefore, it does not appear this disclosure is applicable. Please revise***

<u>Response:</u>

The Company has revised the information.

*We may be unable to retain our future customers and to attract new customers…, page 11*

**We may be unable to complete our preclinical and clinical investigations and fail to generate …, page 12**

***12. We note your reference to "the drugs" in this risk factor. Please clarify whether your feed additive product will be classified as a pharmaceutical product, if approved.***

<u>Response:</u>

We have revised the risk factor and considered it irrelevant.

**We will incur increased costs associated with, and our management will need to devote substantial time and effort to …, page 15** 

**13*. We note your statement that you estimate you will incur up to approximately $200,000 in expenses on an annual basis as a direct result of the requirements of being "a publicly traded company". Please expand your disclosure to explain how you plan to fund such expenses in the near future and reconcile with the information provided in the Use of Proceeds table on page 26 which reflects SEC reporting and compliance costs of only $10,000. Please also explain the consequences of not complying with the reporting obligations applicable to the company after the registration statement is declared effective, including those obligations arising under the Securities Exchange Act of 1934.***

<u>Response:</u>

The Company has revised the disclosure. The information provided in the 'Use of Proceeds' on page 25 and the following risk factor state approximate expenses for a period of one year.

*Based on currently available information and assumptions, we estimate…, page 13.*

*If we are not successful in raising funds from this offering, Mr. Bilinski formally agreed to …, page 20*

**MAGA and CHASIS may prove to be difficult to effectively commercialize as planned., page 18**

***14. We note the third bullet of this risk factor which references "reimbursement and medical policy changes that may adversely affect the pricing, profitability or commercial appeal of MAGA and CHASIS". Please revise your disclosure to explain how reimbursement and medical policies will apply to your product.***

<u>Response:</u>

The Company has revised the risk factor.

*MAGA and CHASIS may prove to be difficult to effectively commercialize as planned…, page 16*

**The proceeds from this offering may be insufficient to achieve substantial revenues and profitable operations..., page 22**

***15. We note your statement that you require minimum funding of approximately $25,000 to conduct your proposed operations for a period of one year. Please expand this risk factor to clarify the consequences to investors if you raise less than $25,000 in this offering.***

<u>Response:</u>

The Company has expanded the risk factor mentioned below.

*The proceeds from this offering may be insufficient to achieve substantial revenues…, page 20*

**Use of Proceeds, page 26**

***16. Please address the following in relation to your Use of Proceeds disclosure:***

 ****

***• We note your statement on page 26 that you expect the minimum proceeds from the offering of $25,000 to fund your needs for the following 12 months. However, after the chart you state that the figures represent costs for the next 24 months. Please reconcile.***

<u>Response:</u>

The Company has updated the information. The estimate costs $25,000 to conduct our proposed operations for a period of one year.

 ****

***• Please confirm, if true, that proceeds will not be used towards the development of the product. Please also revise the Summary section to clarify this point. -***

<u>Response:</u>

The Company will use proceeds to cover top-priority expenses. Please see page 24.

***• The offering expenses row of the chart reflects expenses of $8,000; however, following the chart you estimate the costs of the offering "at about $40,000". Please reconcile.***

<u>Response:</u>

The Company has updated the information. The Company estimated the offering costs at $8,000.

 ****

***• Explain why Marketing and Sales are included in the chart when elsewhere you state that clinical trials will be required prior to commercialization of the company's product.***

<u>Response:</u>

The Company has revised the information. Mag Magna Corp. is planning to expand activities for distributing, marketing, and selling the 'CHASIS' and 'MAGA' components firstly, seeking strategic partners engaged in the development and manufacture of chemical compounds for feed additives becoming a prime focus. Specifically, the Company plans to establish and grow future partner relationships with companies, ready and willing to introduce alternatives to antibiotic feed additives.

**Capitalization, page 27**

***17.***  ***Please revise your capitalization table for the following:***

***• remove current assets as they are not a part of your capitalization. If you choose to present cash and cash equivalents in the table, double underline as it is not part of your capitalization;***

***• only include the loan payable from related parties in the capitalization table; and***

***• reconcile the balance sheet information presented within this table to agree to your unaudited financial statements as of July 31, 2022. For example, net income in the table does not agree with net income presented on page F-1 or F-2. In addition, subscription receivable is not presented on page F-1.***

<u>Response:</u>

The Company has updated the information according to the financial statements as of October 31, 2022.

**Dilution, page 27**

***18.***  ***Please revise here and throughout the filing to present your net historical net tangible book value per share of common stock and loss per share amounts rounded to the nearest cent (i.e., using only two decimal points), in order not to imply a greater degree of precision than exists.***

 ****

<u>Response:</u>

The Company has updated net historical net tangible book value per share of common stock and loss per share amounts rounded to the nearest cent according to the financial statements as of October 31, 2022.

 ****

***19.*** ***Please reconcile for us how you calculated your historical net tangible book value as of July 31, 2022 to be ($1,508.00). Based upon your reported historical net tangible book value and net offering proceeds of $17,000 at the 25% of shares sold from the maximum offering available, please reconcile for us how you determined the $6,492 of post offering net tangible book value as of July 31, 2022. Please review the calculations within the other scenarios of your offering sold as applicable.***

<u>Response:</u>

The Company has updated the information according to the financial statements as of October 31, 2022. Historical Net Tangible Book Value means the total net tangible assets reflected on October 31, 2022, Balance Sheet less an amount equal to the total liabilities reflected on the October 31, 2022 Balance Sheet. Post-offering net tangible book value as of October 31, 2022, means the difference between the capital contributed by the purchasers of the shares and the proceeds of the offering, adding to this the historical net book value as of October 31, 2022.

**Management's Discussion and Analysis of Financial Condition and Results of Operations, page 28**

***20.*** ***Please revise your filing to include all the disclosures required by Item 303(b) and (c) of Regulation S-K, such as liquidity and capital resources and results of operations for each reporting period presented.***

 ****

<u>Response:</u>

The Company has updated the information.

 ****

***21.*** ***Under the header "Critical Accounting Policies and Significant Judgments and Estimates", you state "we believe that the following accounting policies are the most critical for fully understanding and evaluating our financial condition and results of operations" however no such accounting policies are described. Please revise your disclosure accordingly***

<u>Response:</u>

The company has revised the information, indicating that it refers to the accounting policy specified in Note 3 to our audited financial statement and Note 3 to our unaudited interim condensed financial statements.

**Business Overview, page 31** 

***22. We note your disclosure regarding the Patent License and Assignment Agreement with Ipax LLC. Please revise your disclosure to include all material terms of the agreement, including the term and termination provisions as well as payment obligations of each party. Additionally, file a copy of the agreement as an exhibit. See Item 601(b)(10) of Regulation S-K for guidance***

<u>Response:</u>

The Company has added the disclosure and filed Patent License and Assignment Agreement as Exhibit 10.2.

*On November 15, 2022, Mag Magna Corp. entered into a Patent License and Assignment…, page 32*

**Management Executive Officers and Directors, page 33** 

***23. Please revise your disclosure in this section to provide all of the information required by Item 401(e) of Regulation S-K. For instance, we note your statement that Oleg Bilinski has "been focused on commercial and residential real estate investments in Europe and North America" since 2010; however no further detail is provided. In addition, you state that since 2005 Mr. Bilinski" has consulted public companies in the area of SEC compliance, business development, and mergers and acquisitions" without further detail about what companies he consulted with or for. Finally, as Mr. Bilinski does not appear to have agricultural or pharmaceutical experience, please clarify the specific experience, qualifications, attributes or skills that led to the conclusion that Mr. Bilinski should serve as a director of the company.***

<u>Response:</u>

The Company has updated the information about Oleg Bilinski.

*Mr. Bilinski holds an MSc degree in Specialty Microbiology and Chemistry from the National University of Lviv …, page 33* 

**Balance Sheets, page F-2** 

 ****

***24.***  ***Total Assets balance does not agree with Total Liabilities and Stockholders' Deficit balance on your audited balance sheet at April 30, 2022. Please revise.***

<u>Response:</u>

The Company has updated the information.

***25.*** ***Net Income on the Balance Sheet at July 31, 2022 does not agree with Net Income on your Statement of Operations for the period ended July 31, 2022. Please revise.***

<u>Response:</u>

Net Income on the Balance Sheet on July 31, 2022, includes the period from inception September 20, 2021, till April 30, 2022. Net Income on Statement of Operations consists of April 30, 2022 - July 31, 2022 period.

**Notes to the Financial Statements** 

**Note 3. Summary of Significant Accounting Policies, page F-6** 

***26.***  ***We note from page F-2 that you have capitalized $2,950 of website development costs and classified them as fixed assets. Please revise your filing to include your accounting policies related to fixed assets. In addition, please support your basis, citing relevant accounting literature, for capitalizing website development costs as fixed assets rather than intangible assets. Refer to the guidance in ASC 350-50.***

<u>Response:</u>

The company has revised the costs of developing a website as Intangible Assets and added our disclosure of ASC 350-50 to Note 3 to our audited financial statements and Note 3 to our unaudited interim condensed financial statements.

**Exhibits**

***27. We note from Exhibit 23.1 that you include the actual report of your independent registered public accounting firm rather than your auditors' consent. Please obtain and file a revised currently dated consent from your auditors that references the appropriate financial statements and audit report date.***

 **

<u>Response:</u>

The Company has filled the auditor's consent with this Amendment No. 1.

**General**

***28. Please provide us with copies of all written communications, as defined in Rule 405 under the Securities Act, that you, or anyone authorized to do so on your behalf, present to the potential investors in reliance on Section 5(d) of the Securities Act, whether or not they retain copies of the communications.***

 **

<u>Response:</u>

As of date, we have not had any written communications with the potential investors.

 **

***We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.***

 

***Refer to Rules 460 and 461 regarding requests for acceleration. Please allow adequate time for us to review any amendment prior to the requested effective date of the registration statement.***

 ****

***You may contact Tara Harkins at 202-551-3639 or Sasha Parikh at 202-551-3627 if you have questions regarding comments on the financial statements and related matters. Please contact Cindy Polynice at 202-551-8707 or Laura Crotty at 202-551-7614 with any other questions.***

---

| | |
|:---|:---|
| **MAG MAGNA CORP.** | **MAG MAGNA CORP.** |
| By: | /s/ Oleg Bilinski |
|  | Oleg Bilinski |
|  | Chief Executive Officer, Secretary, Treasurer and Director |

---